<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_SJBS1545 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi J Biol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Saudi J Biol Sci</journal-id><journal-title-group><journal-title>Saudi Journal of Biological Sciences</journal-title></journal-title-group><issn pub-type="ppub">1319-562X</issn><issn pub-type="epub">2213-7106</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6997863</article-id><article-id pub-id-type="publisher-id">S1319-562X(19)30328-6</article-id><article-id pub-id-type="doi">10.1016/j.sjbs.2019.12.028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Diabetes as a risk factor for Alzheimer&#x02019;s disease in the Middle East and its shared pathological mediators</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Jayaraj</surname><given-names>Richard L.</given-names></name><email>richardlj@uaeu.ac.ae</email></contrib><contrib contrib-type="author" id="au010"><name><surname>Azimullah</surname><given-names>Sheikh</given-names></name><email>azim.sheikh@uaeu.ac.ae</email></contrib><contrib contrib-type="author" id="au015"><name><surname>Beiram</surname><given-names>Rami</given-names></name><email>rbeiram@uaeu.ac.ae</email><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="af005">Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O Box 17666, Al Ain, United Arab Emirates. <email>rbeiram@uaeu.ac.ae</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>26</day><month>12</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>2</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>26</day><month>12</month><year>2019</year></pub-date><volume>27</volume><issue>2</issue><fpage>736</fpage><lpage>750</lpage><history><date date-type="received"><day>28</day><month>10</month><year>2019</year></date><date date-type="rev-recd"><day>14</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Published by Elsevier B.V. on behalf of King Saud University.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder/><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ab005"><p>The incidence of Alzheimer&#x02019;s disease (AD) has risen exponentially worldwide over the past decade. A growing body of research indicates that AD is linked to diabetes mellitus (DM) and suggests that impaired insulin signaling acts as a crucial risk factor in determining the progression of this devastating disease. Many studies suggest people with diabetes, especially type 2 diabetes, are at higher risk of eventually developing Alzheimer's dementia or other dementias. Despite nationwide efforts to increase awareness, the prevalence of Diabetes Mellitus (DM) has risen significantly in the Middle East and North African (MENA) region which might be due to rapid urbanization, lifestyle changes, lack of physical activity and rise in obesity. Growing body of evidence indicates that DM and AD are linked because both conditions involve impaired glucose homeostasis and altered brain function. Current theories and hypothesis clearly implicate that defective insulin signaling in the brain contributes to synaptic dysfunction and cognitive deficits in AD. In the periphery, low-grade chronic inflammation leads to insulin resistance followed by tissue deterioration. Thus insulin resistance acts as a bridge between DM and AD. There is pressing need to understand on how DM increases the risk of AD as well as the underlying mechanisms, due to the projected increase in age related disorders. Here we aim to review the incidence of AD and DM in the Middle East and the possible link between insulin signaling and ApoE carrier status on A&#x003b2; aggregation, tau hyperphosphorylation, inflammation, oxidative stress and mitochondrial dysfunction in AD. We also critically reviewed mutation studies in Arab population which might influence DM induced AD. In addition, recent clinical trials and animal studies conducted to evaluate the efficiency of anti-diabetic drugs have been reviewed.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Diabetes mellitus</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Insulin signaling</kwd><kwd>Arab population</kwd><kwd>Anti-diabetic drugs</kwd></kwd-group><kwd-group id="kg010"><title>Abbreviations</title><kwd>AD, Alzheimer&#x02019;s disease</kwd><kwd>DM, Diabetes mellitus</kwd><kwd>Pit-PET, Pittsburgh compound B- positron emission tomography</kwd><kwd>FDG-PET, Fluorodeoxyglucose- positron emission tomography</kwd><kwd>MRI, Magnetic resonance imaging</kwd><kwd>IR, Insulin resistance</kwd><kwd>CSF, Cerebrospinal fluid</kwd><kwd>A&#x003b2;, Amyloid-beta</kwd><kwd>T1DM, Type 1 Diabetes Mellitus</kwd><kwd>T2DM, Type 2 Diabetes Mellitus</kwd><kwd>MENA, Middle East North African</kwd><kwd>AGPAT1, 1-acyl-<italic>sn</italic>-glycerol-3-phosphate acyltransferase alpha</kwd><kwd>NOTCH4, Neurogenic locus notch homolog protein 4</kwd><kwd>LPA, Lipophosphatidic acid</kwd><kwd>MCI, Myocardial infarction</kwd><kwd>BMI, Body mass index</kwd><kwd>FTO, Fat Mass and Obesity Associated Gene</kwd><kwd>TCF7L2, Transcription Factor 7 Like 2</kwd><kwd>PPAR-&#x003b3;2, Peroxisome proliferator-activated receptor gamma 2</kwd><kwd>ADAMTS9, ADAM Metallopeptidase With Thrombospondin Type 1 Motif 9</kwd><kwd>DUSP9, Dual Specificity Phosphatase 9</kwd><kwd>GNPDA2, Glucosamine-6-phosphate deaminase 2</kwd><kwd>MC4R, Melanocortin 4 receptor</kwd><kwd>TFAP2B, Transcription Factor AP-2 Beta</kwd><kwd>ApoE, Apolipoprotein E</kwd><kwd>ABCA1, ATP binding cassette subfamily A member 1</kwd><kwd>IGF-1, Insulin-like growth factor 1</kwd><kwd>BACE1, Beta-secretase 1</kwd><kwd>IDE, Insulin degrading enzyme</kwd><kwd>BBB, Blood-Brain Barrier</kwd><kwd>GLP-1, Glucagon like peptide</kwd><kwd>ECE-1, Endotherin converting enzyme 1</kwd><kwd>NFT, Neurofibrillary tangles</kwd><kwd>GSK-3&#x003b2;, Glycogen synthase kinase 3 beta</kwd><kwd>IR, Insulin receptor</kwd><kwd>PI3K, Phosphoinositide-3</kwd><kwd>PP2A, Protein phosphatase 2</kwd><kwd>AAV, Adeno-associated virus</kwd><kwd>CIP2A, Cancerous Inhibitor Of Protein Phosphatase 2A</kwd><kwd>FRMD4A, FERM Domain Containing 4A</kwd><kwd>NF-&#x003ba;B, nuclear factor kappa-light-chain-enhancer of activated B cells</kwd><kwd>MG-H1, Methylglyoxal-hydroimidazolone isomer trifluoroactic acid salt</kwd><kwd>NDUFS3, NADH:Ubiquinone Oxidoreductase Core Subunit S3</kwd><kwd>COX-2, Cyclooxygenase 2</kwd><kwd>CALR, calreticulin gene</kwd><kwd>SORT, Sortilin</kwd><kwd>RAB1A, Ras-related protein 1A</kwd><kwd>STZ, Streptozotocin</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">Alzheimer&#x02019;s disease (AD) is the most common cause of dementia worldwide and it affects 3% of the population aged between 65 and 74&#x000a0;years. The most common symptoms of AD include progressive impairment of cognitive abilities such as memory, judgement, communication and ultimately death. Alzheimer&#x02019;s disease not only affects a person&#x02019;s living ability but it also causes a substantial economic burden to the society. Globally, it is estimated that the total economic cost for AD raised from US$279.6 billion to US$948 billion in 2016. Pathologically, AD is characterized by (1) specific neuronal loss in temporo-parietal association cortices and in the medial temporal lobe structures (2) presence of extracellular plaques made up of aggregated amyloid-beta protein (A&#x003b2;1-42) and (3) presence of intraneuronal tangles composed of truncated and hyperphosphorylated tau (<xref rid="b0590" ref-type="bibr">Lashley et al., 2018</xref>). In normal physiological state, there is an equilibrium between production and degradation of excess amyloid beta (A&#x003b2;) and tau levels but during disease activity, this harmony is disturbed leading to protein aggregation, neuroinflammation and neurodegeneration. Several other neurodegenerative diseases such as Parkinson&#x02019;s disease dementia (PDD), frontotemporal dementia (FTD) and dementia with lewy bodies (DLB) have symptoms similar to AD. These neurodegenerative diseases often occur with substantial degree of co-morbidity, implying the presence of other pathological proteins co-acting in the same brain causing cognitive loss (<xref rid="b0585" ref-type="bibr">Lashley et al., 2008</xref>). Though there are numerous studies on AD pathogenesis, the exact neurodegenerative mechanisms are still unclear which makes definitive diagnosis difficult. Until now, treatment of AD using pharmacological interventions (Donepezil, galantamine, memantine, rivastigmine) have been modest and consistent providing symptomatic relief (<xref rid="b1015" ref-type="bibr">Yiannopoulou and Papageorgiou, 2013</xref>)to the patients but disease-modifying therapies using pharmacological or non-pharmacological approach are considered as a worldwide necessity.</p><p id="p0010">Since 1984, AD has been diagnosed based on National Institute of Neurological and Communicable Disorder and Stroke and the Alzheimer&#x02019;s Disease and Related Disorders association (NINCDS-ADRDA) criteria which intervenes disease state as &#x0201c;possible&#x0201d;, &#x0201d;probable&#x0201d; and &#x0201c;definitive&#x0201d; based on clinical as well as neuropathological patterns (<xref rid="b0830" ref-type="bibr">Reitz and Mayeux, 2014</xref>). Apart from NINCDS-ADRDA scale, clinical diagnosis of AD is performed using three biomarkers tests, (1) cerebrospinal fluid (CSF) A&#x003b2; detection and cerebral PiB-PET representing amyloid metabolism (<xref rid="b0765" ref-type="bibr">Palmert et al., 1990</xref>, <xref rid="b0810" ref-type="bibr">Price et al., 2005</xref>) (2) FDG-PET representing the status of cerebral glucose metabolism (<xref rid="b0700" ref-type="bibr">McKhann et al., 2011</xref>) and (3) CSF Tau detection and structural MRI presenting neurodegeneration (<xref rid="b0845" ref-type="bibr">Rosenmann, 2012</xref>). Though these biomarkers can enhance the possibility of AD diagnosis, due to several shortcomings (expensive, difficult to perform) they are not recommended for conventional diagnosis (<xref rid="b0810" ref-type="bibr">Price et al., 2005</xref>). In addition, after clinical diagnosis, the mean life expectancy of AD patients is approximately 7&#x000a0;years with only 3% of patients living more than 14&#x000a0;years and by that time it is already too late to treat the disease (<xref rid="b0525" ref-type="bibr">Khan and Alkon, 2015</xref>). Patients with metabolic disorders such as diabetes mellitus, hypertension, and obesity have higher risk of AD. Hence, specific biomarkers from patients with metabolic disorders that can detect or prevent AD progression at earlier stage are imperative. Various studies have demonstrated that insulin resistance (IR) and impaired insulin signaling acts as a major pathological factor in both DM and AD. The influence of IR on plasma and CSF AD biomarkers were evaluated in 28 IR and 30 non-IR Finnish men recruited from Metabolic Syndrome in Men (METSIM) study. CSF AD biomarkers such as total tau, phosphorylated tau at Thr181 epitope, A&#x003b2; were quantified with respect to IR. However, no difference were noted in CSF AD biomarkers between IR and non-IR group but plasma insulin correlated with CSF A&#x003b2;/tau in the whole cohort with 487 plasma and 200 CSF proteins differentially expressed in the two groups. This study concluded that in cognitively healthy men, IR is not directly related to level of CSF AD pathology (<xref rid="b0990" ref-type="bibr">Westwood et al., 2017</xref>). Similarly, levels of A&#x003b2; 42, phospoTau, soluble low density lipoprotein receptor related protein 1 (sLRP1) and macrophage-colony stimulating factor (MSCF) were evaluated in CSF and serum of patients with Type 1 Diabetes Mellitus (T1DM) with determinants of cognitive function and white matter integrity. CSF levels of AD biomarkers such as A&#x003b2;-42, pTau and sLRP1 were higher in patients with T1DM with no difference in MCSF. However, CSF-sLRP1 were associated with improved attention, information processing and increased white-matter integrity of right inferior fronto-occipital tract. Whereas, elevated tau levels was associated with white-matter integrity of right inferior fronto-occipital tract. However, these observed profile mismatches with the full risk profile as seen in pre-AD patients (<xref rid="b0760" ref-type="bibr">Ouwens et al., 2014</xref>). Since, DM serves as a major risk factor for AD, various clinical cognitive biomarkers are evaluated in DM patients for early AD diagnosis. Recently, detailed review by Zhao et al summarized most of the available clinical biomarker studies on diabetic patients with cognitive decline that can be further developed and used for diagnostic and therapeutic purposes (<xref rid="b1045" ref-type="bibr">Zhao et al., 2017</xref>). Thus, to prevent late-stage diagnosis, it is imperative to identify biomarkers at pre-clinical stage (with detectable pathological alteration but without cognitive impairment) to prevent metabolic disease induced AD progression. Various pathological factors such as ApoE mutation, aggregation of amyloid beta and tau, neuroinflammation, oxidative stress and mitochondrial dysfunction plays a major role in increasing the risk of diabetes induced AD. These factors and the pathological mechanisms involved have been discussed in detail in this review.</p></sec><sec id="s0010"><label>2</label><title>Burden of Alzheimer&#x02019;s disease in the Middle East</title><p id="p0015">According to a 2014 study, AD affects as many as one in seven of people aged over 60 in the United Arab Emirates (UAE), with an estimated total societal of 403 million dirhams, and the burden and the burden will exponentially increase due to healthcare development (<xref rid="b0010" ref-type="bibr">Abyad, 2016</xref>). Most individuals with the disease are 65 and older, and after age 65, the risk of AD doubles every five years. After age 85, the risk reaches nearly one-third. In 35&#x02013;40&#x000a0;years, the adult population in the Middle East will go up in the population pyramid resulting in more number of elderly population in the Middle East, possibly due to increase in longevity and improvements in public health. (<xref rid="b0010" ref-type="bibr">Abyad, 2016</xref>) World Health organization predicted that between 2000 and 2050, there will be 4&#x02013;5% increase in the rate of ageing above 65&#x000a0;years with a normal yearly development rate exceeding 5% in Arab nations (<xref rid="b0395" ref-type="bibr">Hajjar et al., 2013</xref>). Unfortunately, there are only few studies in the Middle East/North Africa (MENA) region evaluating the prevalence of dementia in these regions. A recent multi-language review and feasible analysis on the incidence of dementia in MENA concluded that there is none to little information in dementia incidence (<xref rid="b0125" ref-type="bibr">Bhalla et al., 2018</xref>). Abyad et al concluded that out of 800 patients, 10% had dementia prevalence in Lebanon. Following this, a similar study was replicated in Dubai and AD prevalence was found to be 3%, 2% rest of dementia and stroke affecting 5% of the study group. However, 40% of the study group had memory problems and 20% had decline in decision making as well (<xref rid="b0010" ref-type="bibr">Abyad, 2016</xref>). In 2018, Phung et al analyzed dementia prevalence in Lebanon with 502 persons older than 65&#x000a0;years. Illiteracy among the older generations of MENA population is high and hence Arabic version of the one-stage 10/66 Dementia Research group (DRG) diagnostic assessment for dementia was used to minimize the effect of culture and education on cognitive assessment. Crude dementia prevalence was found to be 7%, and 9% had age-standardized dementia prevalence (<xref rid="b0785" ref-type="bibr">Phung et al., 2017</xref>). Currently, there are no available treatments to stop or reverse the progression of the disease, which worsens as it progresses, and eventually leads to death. Alzheimer disease community organization reported that three thousand cases are diagnosed in the UAE in 2016 alone and they have encouraged elderly population in UAE to engage in cognitive activities as much as possible. Though this value seems to be low, the burden of the disease is projected to increase exponentially. Angiotensin-converting enzyme (ACE) gene polymorphism is closely associated with AD in Israeli Arab community. Angiotensin converting enzyme, an dipeptidyl carboxypeptidase plays a major role in blood pressure regulation. Clinical study have shown that Alu insertion/deletion (I/D) polymorphism of ACE gene (DCP1) increases the risk of DM in Saudi Arabian population (<xref rid="b0065" ref-type="bibr">Al-Saikhan et al., 2017</xref>). Similarly, fifteen single nucleotide polymorphism in DCP1 was evaluated in 92 patients with AD and 166 non-demented controls. There was a significant association with SNPs rs4343 (P&#x000a0;=&#x000a0;.00001) and rs4351 (P&#x000a0;=&#x000a0;.01). Haplotype analysis showed that individual possessing &#x0201c;GA&#x0201d; haplotype derived from these SNPs had 45-fold higher risk of incidence of AD. This study suggests that a variant in close proximity to rs4343 and rs4351 might regulate the risk of AD in Israeli Arab community (<xref rid="b0720" ref-type="bibr">Meng et al., 2006</xref>). The same group performed autozygosity mapping using Genome wide SNP Data from Israeli-Arab community to identify novel genetic mutations for AD. Though <italic>APOE-&#x003b5;4</italic> frequency is low in Wadi Ara (Arab community in northern Israel), this population have high frequency of AD. Hundred and twenty-four AD cases along with 142 controls were genotyped for a genome wide set of more than 300,000 SNPs to identify the region of autozygosity (identical allele or chromosomal segments of DNA). Seven different chromosomes with eight autozygous regions were frequent in controls and whereas 105 SNPs, mostly in chromosome 6 and 9 were associated with AD. Meta-analysis of four genome wide associated study datasets proved association of SNPs in <italic>AGPAT1</italic> AGPAT1 (1-acyl-<italic>sn</italic>-glycerol-3-phosphate acyltransferase alpha) and <italic>NOTCH4</italic> ((Neurogenic locus notch homolog protein 4))., an transmembrane protein of endoplasmic reticulum catalyzes the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (<xref rid="b0015" ref-type="bibr">Aguado and Campbell, 1998</xref>). Lysophosphatidic acid enhances tau phosphorylation during neurite retraction (<xref rid="b0870" ref-type="bibr">Sayas et al., 1999</xref>). NOTCH4 is involved in various developmental processes by modulating cell fate decisions. Gamma-secretase (&#x003b3;-secretase) regulates intramembrane proteolysis of <italic>NOTCH4</italic> and &#x003b3;-secretase is involved in final cleavage of A&#x003b2; peptide from amyloid precursor protein, which is responsible for A&#x003b2; oligomer toxicity (<xref rid="b0580" ref-type="bibr">Lambert et al., 2004</xref>). Hence, SNPs in <italic>AGPAT1</italic> and <italic>NOTCH4</italic> might enhance the risk of AD in Israeli-Arab population. In a similar Wadi Ara population door-to-door survey involving 906 participants, 297 had MCI (33%), 95 had AD (10%) and hypertension was a major risk factor for AD (<xref rid="b0475" ref-type="bibr">Inzelberg et al., 2015</xref>). However, more clinical studies are needed in the Arab population to understand how metabolic disorders and genetic mutations could contribute to AD. Out of different metabolic disorders, diabetes remains as a major risk factor for AD because insulin-signaling impairment plays a major role in cognitive impairment and AD. Thus, AD is also termed as Type 3 Diabetes since both AD and diabetes share common pathomechanisms. The impact of DM in MENA region is reviewed below to understand the current and forecasted risk of incidence of AD in this region.</p></sec><sec id="s0015"><label>3</label><title>Diabetes mellitus in the Middle East and its possible links with AD</title><p id="p0020">Worldwide, 382 million people are affected by diabetes in which 90% are Type 2 Diabetes Mellitus (T2DM) (<xref rid="b0080" ref-type="bibr">Atlas, 2015</xref>). The incidence of T2DM in the UAE is projected to increase from 18.7% to 21.4% by 2030 (<xref rid="b0650" ref-type="bibr">Lotfy et al., 2017</xref>). Cardiovascular screening program of UAE Emiratis in Abu Dhabi showed more age-standardized prevalence of pre-diabetes (30%) and diabetes (25%) defined as fasting blood glucose (5.6&#x02013;6.9&#x000a0;mmol/l) or 2&#x000a0;h post oral glucose tolerance test (7.8&#x02013;11&#x000a0;mmol/l) (<xref rid="b0390" ref-type="bibr">Hajat et al., 2012</xref>). Similar projection have been reported in most of the MENA regions as well (<xref rid="b0055" ref-type="bibr">Alhyas et al., 2012</xref>). Saudi Arabia have higher prevalence of DM (23.9%) whereas, Egypt have largest number of DM patients. United Arab Emirates, Kuwait, Qatar and Bahrain were the countries with highest spending ($2000&#x02013;7000) for DM per person per year (<xref rid="b0080" ref-type="bibr">Atlas, 2015</xref>). Incidence of DM have increased dramatically due to accelerated economic lifestyle changes that results in reduced physical activity, more intake of refined carbohydrates, obesity and ageing population (<xref rid="b0050" ref-type="bibr">Alhyas et al., 2011</xref>). Out of 34 million people diagnosed by diabetes in the MENA region, 17 million were undiagnosed that might result in increase in risk of diabetes induced disorders (<xref rid="b0670" ref-type="bibr">Majeed et al., 2014</xref>). Unusually, prevalence of T2DM is high in Arab children less than 18&#x000a0;years due to high weight and obesity (<xref rid="b0040" ref-type="bibr">Al Amiri et al., 2015</xref>). Central adiposity is common in Arab population that plays a major role in development of obesity and diabetes. Out of various modifiable risk factors, obesity have major influence on incidence of T2DM in which insulin resistance plays an important pathological role. Though genetic studies in MENA region is limited, it is reported that variation in <italic>ADIPOQ</italic> gene (encodes for adiponectin) is closely associated with high waist circumference and increased BMI in Arabs (<xref rid="b1025" ref-type="bibr">Zadjali et al., 2013</xref>). Adiponectin is released by adipocytes and it is observed to be lower in obese subjects. An Emirati population based study involving 259 Emiratis demonstrated that there is association between FTO rs9939609 A/A genotype with insulin resistance and impaired fasting glucose (<xref rid="b0855" ref-type="bibr">Saber-Ayad et al., 2019</xref>). FTO gene rs9939609 (A&#x000a0;&#x0003e;&#x000a0;T) is known for its important role in obesity development and insulin resistance (<xref rid="b0335" ref-type="bibr">Frayling et al., 2007</xref>, <xref rid="b0895" ref-type="bibr">Shimaoka et al., 2010</xref>). In a similar Emirati population based study, the association between <italic>TCF7L2</italic> (Transcription factor 7 like 2) polymorphism and diabetes were analyzed by genotyping two <italic>TCF7L2</italic> SNPs rs12255372 and rs7903146 in 368 adult subjects. Diabetes mellitus was slightly significantly associated with frequency of the T variant at rs12255372 but not at rs7303146. Combined DM/Pre-DM data compared to controls resulted in close association of rs12255372 with risk of DM. Hence, <italic>TCF7L2</italic> variants are associated with more risk for DM in Emirati subjects but not associated with insulin resistance (<xref rid="b0850" ref-type="bibr">Saadi et al., 2008</xref>). Conversely, Damcott et al., reported that in Amish subjects, <italic>TCF7L2</italic> risk variant may be involved in adipocyte dysfunction resulting in triglycerides deposition and insulin resistance (<xref rid="b0270" ref-type="bibr">Damcott et al., 2006</xref>). However, some studies report little-to-no association between <italic>TCF7L2</italic> risk variant and insulin resistance (<xref rid="b0970" ref-type="bibr">Varghese et al., 2016</xref>, <xref rid="b0070" ref-type="bibr">Alsmadi et al., 2008</xref>). Apart from <italic>TCF7L2</italic>, peroxisome-proliferator-activated receptors-&#x003b3;2 (PPAR-&#x003b3;2) have a major effect on T2DM incidence. To understand the influence of PPAR-&#x003b3;2 on Emirati population, a case control study was performed to predict the association of variants <italic>Pro12Ala</italic> (rs1801282) of <italic>PPAR-&#x003b3;2</italic> with T2DM risk. This study concluded that <italic>Pro12Ala</italic> mutation in <italic>PPAR-&#x003b3;2</italic> is not associated with risk of incidence of T2DM in Emirati population (<xref rid="b0060" ref-type="bibr">Al-Safar et al., 2015</xref>). However, <italic>Pro12Ala</italic> polymorphism have been reported to be associated with obesity, insulin sensitivity in various population (<xref rid="b0865" ref-type="bibr">Sanghera et al., 2008</xref>, <xref rid="b0430" ref-type="bibr">Herder et al., 2008</xref>). Genome-wide genetic analysis of metabolic traits in Arab population is extensively reviewed elsewhere (<xref rid="b0425" ref-type="bibr">Hebbar et al., 2019</xref>). However, certain T2DM risk loci such as <italic>ADAMTS9</italic> (ADAM metallopeptidase with thrombospondin type 1 motif 9)<italic>, DUSP9</italic> (Dual specificity phosphatase 9) and <italic>PPAR-&#x003b3;</italic> that has the ability to modulate insulin action and certain risk loci such as <italic>FTO, GNPDA2</italic> (Glucosamine-6-phosphate deaminase 2)<italic>, MC4R</italic> (Melanocortin 4 receptor) and <italic>TFAP2B</italic> (Transcription Factor AP-2 Beta) associated with obesity, BMI and adiposity have been identified (<xref rid="b0425" ref-type="bibr">Hebbar et al., 2019</xref>). Apart from genetic risk loci identification, a simple, non-invasive risk score specific for UAE citizens was developed due to differences in lifestyle and ethnicity to predict individuals with higher risk of having undiagnosed T2DM. The study included 872 UAE citizens and their anthropometric measurements, fasting blood glucose and demographic details were analyzed. The risk score was established using stepwise forward repression model. Northern Emirates had 25.1% DM prevalence and the significant risk factors identified were age (&#x02265;35&#x000a0;years), hypertension, body mass index &#x02265;30.0, family history of DM and waist-to-hip ratio (&#x02265;0.85 for females and &#x02265;0.90 for males). Hence, this scale could be used for earlier detection of DM in high risk population (<xref rid="b0930" ref-type="bibr">Sulaiman et al., 2018</xref>). Recent observational cross-sectional study in Saudi Arabian population demonstrated that population with prevalence of diabetes and obesity had poorer cognitive performance and these observation was independent of gender or educational background (<xref rid="b0045" ref-type="bibr">Alaama et al., 2016</xref>). These studies suggest that there is a close association between obesity, insulin resistance and DM. In addition, SNP&#x02019;s in AD and DM risk genes enhance the risk of incidence neurological disorders such as AD in the Middle East (<xref rid="t0005" ref-type="table">Table 1</xref>). In addition, DM is closely associated with progression of white matter hyperintensities (WMH) volumes in elderly patients and WMH progression is positively correlated with cognitive dysfunction and impairment of activities of daily living (<xref rid="b0360" ref-type="bibr">Gouw et al., 2008</xref>, <xref rid="b0570" ref-type="bibr">Kreisel et al., 2013</xref>). Apart from genetic association between insulin resistance and T2DM, various pathological factors such as ApoE, A&#x003b2;, Tau, inflammation, mitochondrial dysfunction and oxidative stress enhance the risk of DM patients to neurological disorders. However, more research is needed to understand the pathological mechanisms, role of SNP&#x02019;s in Middle Eastern population that might play a crucial role in preventing DM induced AD.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Single Nucleotide Polymorphisms in genes that acts as a major risk factor for AD and DM development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>GENE</th><th>PUTATIVE FUNCTION</th><th>SNP&#x02019;s</th><th>RISK FACTOR FOR DM/AD</th><th>REFERENCE</th></tr></thead><tbody><tr><td>ACE1</td><td>Blood pressure regulation</td><td>rs4343, rs4351</td><td>AD</td><td>(<xref rid="b0720" ref-type="bibr">Meng et al., 2006</xref>)</td></tr><tr><td>FTO</td><td>Adipogenesis and energy homoestasis</td><td>rs9939609</td><td>DM</td><td>(<xref rid="b0855" ref-type="bibr">Saber-Ayad et al., 2019</xref>)</td></tr><tr><td>TCF7L2</td><td>Blood pressure homeostasis</td><td>rs12255372</td><td>DM</td><td>(<xref rid="b0850" ref-type="bibr">Saadi et al., 2008</xref>)</td></tr><tr><td>PPAR-&#x003b3;2</td><td>Regulates fatty acid storage and glucose metabolism</td><td>rs1801282</td><td>Insulin resistance &#x00026; Obesity</td><td>(<xref rid="b0060" ref-type="bibr">Al-Safar et al., 2015</xref>)</td></tr><tr><td>ApoE</td><td>Lipoprotein metabolism</td><td>ApoE 2,3,4</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr><tr><td>BIN1</td><td>Plasma membrane curvature, membrane shaping and membrane remodeling</td><td>rs744373</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr><tr><td>CLU</td><td>Functions as extracellular chaperone that prevents aggregation of non native proteins</td><td>rs11136000</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr><tr><td>ABCA7</td><td>Transportation of various molecules across extra-cellular and intra-cellular membranes</td><td>rs3764650</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr><tr><td>CR1</td><td>Plays major role in capture and clearance of complement-opsonized pathogens</td><td>rs3818361</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr><tr><td>PICALM</td><td>Plays a major role in clathrin-mediated endocytosis</td><td>rs3851179</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr><tr><td>FRMD4A</td><td>Scaffolding protein that regulates epithelial cell polarity</td><td>rs7081208, rs2446581, rs17314229</td><td>AD</td><td>(<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>)</td></tr></tbody></table></table-wrap></p><sec id="s0020"><label>3.1</label><title>Role of Apolipoprotein E4 in T2DM and AD</title><p id="p0025">Apolipoproteins which plays a major role in dyslipidemia are having greater attention in T2DM. Apolipoprotein E, a 34&#x000a0;kDa protein is composed of 299 amino acids and their isoforom difference is based on their amino acid residues; <italic>ApoE-&#x003b5;2</italic> (Cys112, Cys158), <italic>ApoE-&#x003b5;3</italic> (Cys112, Arg158), <italic>ApoE-&#x003b5;4</italic> (Arg112, Arg158). Their single amino acid difference modulate their ability to bind to Amyloid-beta (A&#x003b2;), lipids and receptors (<xref rid="b0340" ref-type="bibr">Frieden and Garai, 2012</xref>, <xref rid="b1060" ref-type="bibr">Zhong and Weisgraber, 2009</xref>). Clinical and pre-clinical studies provide strong evidence that ApoE isoforms affect A&#x003b2; aggregation and clearance. Apolipoprotein E4 (<italic>ApoE-&#x003b5;4</italic>) carrier status interacts synergistically with T2DM causing cognitive impairment in T2DM patients (<xref rid="b0620" ref-type="bibr">Li and Huang, 2016</xref>). Although <italic>ApoE-&#x003b5;4</italic> status alone did not have significant effect on dementia but T2DM patients carrying <italic>ApoE-&#x003b5;4</italic> had greater risk of both AD and vascular dementia when compared to T2DM patients without <italic>ApoE-&#x003b5;4</italic> allele (<xref rid="b0485" ref-type="bibr">Irie et al., 2008</xref>). Pathologically, T2DM and <italic>ApoE-&#x003b5;4</italic> allele synergistically enhanced neuritic plaques and neurofibrillary tangles in hippocampus and A&#x003b2; aggregation in brain. Individuals with T2DM and <italic>ApoE-&#x003b5;4</italic> allele had an higher AD risk ratio of 5.5 compared to T2DM alone or <italic>ApoE-&#x003b5;4</italic> allele carriers alone (<xref rid="b0780" ref-type="bibr">Peila et al., 2002</xref>). Low insulin response was closely associated with higher AD risk and subjects without <italic>ApoE-&#x003b5;4</italic> allele had stronger association (<xref rid="b0840" ref-type="bibr">R&#x000f6;nnemaa et al., 2008</xref>). Moreover, insulin administration to AD subjects with <italic>ApoE-&#x003b5;4</italic> allele had marked memory facilitation when compared to AD group with <italic>ApoE-&#x003b5;4</italic> allele. ApoE mice fed with high fat diet induced insulin resistance had deficit in peripheral metabolism and cognition, impairment in hippocampus dependent spatial learning and memory. Conversely, these cognitive impairments were not found in Type-1 diabetes model suggesting the role of high fat diet induced obesity and insulin resistance in cognitive impairments. Genome-wide measurements of DNA hydroxymethylation from these samples resulted in alterations in glutamate metabolism, purine metabolism and pentose phosphate pathway. However, these alterations were reversed when E4 mice were fed with low fat diet suggesting functional role was affiliated with same metabolic pathways which is involved in high fat diet induced insulin resistance. Thus, E4 carriers are susceptible to metabolic impairments due to insulin resistance (<xref rid="b0500" ref-type="bibr">Johnson et al., 2017</xref>). High fat diet induced peripheral insulin resistance and ApoE impair insulin signaling in the brain. However, upon administration of insulin into the periphery, presence of ApoE reduces cerebral and peripheral responsiveness of insulin-induced signaling. This is due to binding of ApoE to insulin receptor and trapping insulin receptor in endosomes and ApoE enhances insulin receptor aggregation, an endocytic abnormality associated with ageing. Binding of ApoE to insulin receptor also impairs insulin internalization. It has been reported that insulin receptor plays an important role in A&#x003b2; clearance, hence impairment of insulin receptors leads to cerebral A&#x003b2; overload leading to neurodegeneration (<xref rid="b1050" ref-type="bibr">Zhao et al., 2009</xref>). Hence, AD patients with <italic>ApoE-&#x003b5;4</italic> allele had higher amyloid precursor protein levels upon insulin administration when compared to non-<italic>ApoE-&#x003b5;4</italic> AD patients (<xref rid="b0260" ref-type="bibr">Craft et al., 2000</xref>) Presence of <italic>ApoE-&#x003b5;4</italic> allele decreases the expression of insulin degrading enzyme (IDE), an endopeptidase enzyme that degrades A&#x003b2; (<xref rid="b0325" ref-type="bibr">Fernandez-Gamba et al., 2009</xref>). Apolipoprotein E is reported to be the non-fibrillar component of systemic amyloid deposits (<xref rid="b0415" ref-type="bibr">Hatters et al., 2006</xref>) and <italic>ApoE-&#x003b5;4</italic> contributes to less plaque clearance. Oxidative stress is an important initiation factor of toxic pathological events in AD and presence of <italic>ApoE-&#x003b5;4</italic> results in higher oxidative stress (<xref rid="b0035" ref-type="bibr">Akter et al., 2011</xref>). Furthermore, cholesterol transporter protein ABCA1 (ATP-binding cassette subfamily A member 1) influences lipid binding capacity of ApoE. Lipidated ApoE binds to soluble A&#x003b2; and aids in A&#x003b2; clearance. Hence, ABCA1 deficiency leads to poor lipidation of ApoE that results in heavier amyloid burden while overexpression of ABCA1 decreased amyloid burden (<xref rid="b0440" ref-type="bibr">Hirsch-Reinshagen et al., 2005</xref>). In the brain, ApoE is produced by astrocytes to transport cholesterol to neurons via ApoE transporters and hence ApoE is important for synaptogenesis in neurons. Therefore, presence of ApoE isoform may affect synaptic plasticity or neuronal recovery in AD (<xref rid="b0690" ref-type="bibr">Mauch et al., 2001</xref>, <xref rid="b0420" ref-type="bibr">Hayashi et al., 2004</xref>). Whereas, in the peripheral tissues ApoE is produced by macrophages and hepatocytes that might be responsible for difference in function of ApoE in periphery and CNS (<xref rid="b1055" ref-type="bibr">Zhao et al., 2018</xref>). Proteolytic cleavage of <italic>ApoE-&#x003b5;4</italic> by cathepsin D and site-directed antibody cleavage of <italic>ApoE-&#x003b5;4</italic> yielded amino-terminal fragments as seen in AD brain extracts (<xref rid="b0835" ref-type="bibr">Rohn et al., 2012</xref>, <xref rid="b0460" ref-type="bibr">Huang et al., 2001</xref>, <xref rid="b1065" ref-type="bibr">Zhou et al., 2006</xref>). Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) trial demonstrated that lifestyle modification does not play a significant role in cognitive function between <italic>ApoE-&#x003b5;4</italic> carriers versus non-carriers. However, <italic>ApoE-&#x003b5;4</italic> carriers under treatment had significant improvement in certain cognitive measures compared to <italic>ApoE-&#x003b5;4</italic> carriers without treatment (<xref rid="b0905" ref-type="bibr">Solomon et al., 2018</xref>). Therefore <italic>ApoE-&#x003b5;4</italic> respond differently to certain interventions when compared to non-carriers and hence specific prevention strategies for <italic>ApoE-&#x003b5;4</italic> carriers is important. Pharmacological AD prevention studies such as the effect of anti-hypertensive drug on <italic>ApoE-&#x003b5;4</italic> carriers had lower risk of AD compared to non-carriers (<xref rid="b0380" ref-type="bibr">Guo et al., 2001</xref>). It is also important to note that prevalence of hypertension is high in Middle East (<xref rid="b0385" ref-type="bibr">Habibzadeh, 2011</xref>). Cross-Sectional community based study in Al-Ain city of UAE concluded that 20.8% of 817 subjects had hypertension and 23.3% had DM (<xref rid="b0100" ref-type="bibr">Baynouna et al., 2008</xref>). Hence, DM and anti-hypertensive drugs are being studied to understand their efficacy in decreasing cognitive deficits in AD. Diabetes drug pioglitazone was recently tested in TOMORROW Phase III AD prevention clinical trial. Regardless of <italic>ApoE-&#x003b5;4</italic> carrier status, pioglitazone does not prevent progression of patients from normal cognition to MCI due to AD. Hence, TOMORROW Phase III AD was recently discontinued. However, Alzheimer&#x02019;s Prevention Initiative Generation Study will examine the consequence of <italic>ApoE-&#x003b5;4</italic> status on new drugs (CAD106 and CNP520) (<xref rid="b0115" ref-type="bibr">Berkowitz et al., 2018</xref>). Intranasal delivery of long lasting analog, detemir showed that cognitive improvement is dependent on ApoE status (<xref rid="b0230" ref-type="bibr">Claxton et al., 2015</xref>). However, more studies are important to understand the pathological mechanisms linking T2DM, ApoE and AD.</p></sec><sec id="s0025"><label>3.2</label><title>Influence of Amyloid-beta in T2DM and AD</title><p id="p0030">Amyloid beta is produced by sequential cleavage of &#x003b2;-amyloid precursor protein by &#x003b2; and &#x003b3;-secretase. Pathologically AD is characterized by presence of senile plaques (A&#x003b2;) and neurofibrillary tangles (tau). Accumulation of senile plaques (SPs) in the cortices of AD patients are responsible for synaptic degeneration. This results in cognitive impairment due to disturbance in axonal transport of vesicles containing brain derived neurotropic factor and mitochondria (<xref rid="b0410" ref-type="bibr">Hardy and Selkoe, 2002</xref>, <xref rid="b0310" ref-type="bibr">Decker et al., 2010</xref>, <xref rid="b0945" ref-type="bibr">Tang et al., 2012</xref>). Hence, accumulation of cytotoxic A&#x003b2; oligomers and fibrillary aggregates is believed to play a major role in various diseases. However, rather than A&#x003b2; fibrils, memory loss in AD patients is largely due to A&#x003b2; oligomers because long-term potentiation in neurons is inhibited by A&#x003b2; oligomers by interacting with glutamate receptors and impair calcium influx in neurons (<xref rid="b0980" ref-type="bibr">Walsh and Selkoe, 2004</xref>, <xref rid="b0985" ref-type="bibr">Walsh et al., 2002</xref>, <xref rid="b0615" ref-type="bibr">Li et al., 2009</xref>). Deposition of A&#x003b2; in pancreatic islet cells and brain exhibits pathogenic similarity in T2DM and AD respectively (<xref rid="b0105" ref-type="bibr">Beeler et al., 2009</xref>). Post-mortem studies in T2DM patients showed presence of islet amyloid polypeptide and hyperphosphorylated tau in pancreatic islet cells (<xref rid="b0725" ref-type="bibr">Miklossy et al., 2010</xref>). Similarly, amyloid plaques and neurofibrillary tangles were present in hippocampus of T2DM patients (<xref rid="b0780" ref-type="bibr">Peila et al., 2002</xref>). Hyperphosphorylation of tau leads to intracellular buildup of aggregated tau that leads to neuronal loss and dementia in AD (<xref rid="b0675" ref-type="bibr">Mandelkow et al., 1995</xref>). The duration of T2DM is directly correlated with the amount of cerebral amyloid load (<xref rid="b0495" ref-type="bibr">Janson et al., 2004</xref>). Impairment of insulin signaling plays a major role in AD pathology. Post-mortem cases of advanced AD demonstrated deficits in the expression of insulin like growth factor-1 (IGF-1) and IGF-2 peptides, insulin and their receptors followed by abnormalities in downstream insulin signaling mechanisms (<xref rid="b0915" ref-type="bibr">Steen et al., 2005</xref>). Since, these anomalies were also seen in T1DM or T2DM, de la Monte at al coined AD as &#x0201c;type 3 diabetes&#x0201d;.</p><p id="p0035">Defective insulin secretion in &#x003b2;-cell mass and impaired insulin sensitivity in metabolic organs such as muscle and liver are prime causes of T2DM. In addition to peripheral function of insulin, it is also known to regulate synaptic and neuronal function within the cortex, cerebellum and hippocampus and protect neurons from cell death (<xref rid="b1035" ref-type="bibr">Zhao and Alkon, 2001</xref>, <xref rid="b0215" ref-type="bibr">Chiu et al., 2008</xref>). Insulin also acts on &#x003b2;-site amyloid precursor protein cleaving enzyme 1 (BACE1) and &#x003b3;-secretase to regulate A&#x003b2; levels and degrades excess A&#x003b2; by modulating insulin-degrading enzyme (IDE) (<xref rid="b0315" ref-type="bibr">Eckman and Eckman, 2005</xref>, <xref rid="b0320" ref-type="bibr">Farris et al., 2003</xref>). Therefore, insulin signaling impairment in T2DM and AD have a direct effect on A&#x003b2; levels. Mixed mice model of T2DM and AD (APP/PS1xdb/db) showed that aged transgenic mice had impaired metabolic control along with reduced cortical size, reduction in dendritic spine density that leads to learning and memory deficit. These mice also had increased tau phosphorylation, toxic A&#x003b2; load, microglia activation and BBB disruption (<xref rid="b0470" ref-type="bibr">Infante-Garcia et al., 2016</xref>). Similarly, in an mixed AD and DM mice model (APP<sup>+</sup>
<italic>-ob/ob</italic> and APP<sup>+</sup> -NSY), diabetes exacerbated cognitive impairments, enhanced A&#x003b2; levels, decreased brain insulin levels and Akt phosphorylation (important step in insulin signaling) (<xref rid="b0940" ref-type="bibr">Takeda et al., 2010</xref>). Mechanistically, soluble A&#x003b2; oligomers causes loss of insulin receptor (IR) in neuronal processes and inhibits neuronal response to insulin causing deterioration of synaptic function (<xref rid="b1040" ref-type="bibr">Zhao et al., 2008</xref>). Oligomers binding to synapses (in particular neurons) also causes oxidative stress (<xref rid="b0280" ref-type="bibr">De Felice et al., 2007</xref>), tau hyperphosphorylation (<xref rid="b0290" ref-type="bibr">De Felice et al., 2008</xref>)and synapse loss (<xref rid="b0285" ref-type="bibr">De Felice et al., 2009</xref>). Soluble A&#x003b2; oligomers downregulated plasma membrane insulin receptors through calcium calmodulin-dependent kinase II and casein kinase II inhibition. However, insulin administration prevented oxidative stress and synaptic spine deterioration. Submaximal doses of insulin along with rosiglitazone, an insulin-sensitizing drug decreased A&#x003b2; oligomers binding to insulin receptors. Surprisingly, inhibition of tyrosine kinase activity prevented the protective effect of insulin (<xref rid="b0285" ref-type="bibr">De Felice et al., 2009</xref>). However, clinical trials and safety data suggest that rosiglitazone and pioglitazone should not be used for treatment of AD (<xref rid="b0730" ref-type="bibr">Miller et al., 2011</xref>). Neurons exposed to A&#x003b2; oligomers caused serine phosphorylation of insulin receptor substrate-1 (IRS-1), thereby inhibiting downstream insulin signaling and peripheral insulin resistance along with abnormal activation of JNK/TNF-&#x003b1; pathway (<xref rid="b0435" ref-type="bibr">Hirosumi et al., 2002</xref>). However, exendin-4 (an antidiabetic drug) activates insulin signaling through glucagon-like peptide 1(GLP-1) receptors that resulted in normal insulin signaling, prevented cognitive deficits and inverted insulin pathology (<xref rid="b0140" ref-type="bibr">Bomfim et al., 2012</xref>). These studies provide evidence that deterioration of insulin signaling might be responsible for T2DM mediated AD progression. Administration of GLP-1 analog to 38 AD patients in randomized, placebo-controlled, double-blind clinical trial prevented cognitive dysfunction, synapse impairment and disease evolution. (<xref rid="b0350" ref-type="bibr">Gejl et al., 2016</xref>). Recently, patients treated with liraglutide (another GLP-1 agonist) demonstrated a non-significant trend for increased cerebral glucose utilization rate (CMRglc) and the rate of A&#x003b2; deposition was not affected by liraglutide (<xref rid="b0350" ref-type="bibr">Gejl et al., 2016</xref>). However, no firm conclusions on the effect of liraglutide on cognitive scores was drawn from this study. Established animal model showed that intracerebroventricular (icv) injection of streptozotocin (STZ) causes AD like pathology by causing insulin deficiency in pre-clinical studies. For example, icv-injection (3&#x000a0;mg/kg) causes A&#x003b2; oligomer accumulation and enhanced production of carboxy-terminal fragments from APP (<xref rid="b0630" ref-type="bibr">Lin et al., 2014</xref>). STZ injection also decreased the levels of amyloid beta degrading enzyme like endotherin-converting enzyme-1 (ECE-1), insulin degrading enzyme (IDE) in rat cortices (<xref rid="b0635" ref-type="bibr">Liu et al., 2011</xref>). Accumulation of A&#x003b2; in the brain might be due to impairment of endocytosis. Many studies have shown that &#x003b2;-secretase and A&#x003b2; are carried intracellulary via endocytosis and A&#x003b2; cleavage occurs in endosomes (<xref rid="b0375" ref-type="bibr">Grbovic et al., 2003</xref>, <xref rid="b0550" ref-type="bibr">Koh et al., 2005</xref>). Non-human primate T2DM model showed that exacerbated endocytic disturbance causes severe A&#x003b2; load in the brain (<xref rid="b0750" ref-type="bibr">Okabayashi et al., 2015</xref>). Hence, any drug that has the ability to clear or diminish A&#x003b2; oligomers may slow the progression of the disease. Solanezumab, a humanized immunoglobulin G1 monoclonal antibody that has the ability to bind to mid-domain of A&#x003b2; peptide increases the clearance of soluble A&#x003b2; from the brain. In phase three clinical trials (EXPEDITION and EXPEDITION2), solanezumab did not produce significant effect on cognitive function who had mild-to-moderate AD. However, pre-specified pooled analysis showed that solanezumab treated patients had less cognitive decline (34%) and less functional decline (18%) when compared to placebo controls. Third double-blind, placebo-controlled phase 3 trial (EXPEDITION3) study with patients with mild AD was performed. Unfortunately, administration of Solanezumab every 4&#x000a0;weeks with a dose of 400&#x000a0;mg did not significantly affect cognitive decline (<xref rid="b0450" ref-type="bibr">Honig et al., 2018</xref>). However, efforts to develop drugs that can prevent/disintegrate soluble A&#x003b2; oligomers are continuing with a hope for positive clinical trials (<xref rid="b0265" ref-type="bibr">Cummings et al., 2018</xref>).</p></sec><sec id="s0030"><label>3.3</label><title>Effect of tau hyperphosphorylation in T2DM and AD</title><p id="p0040">Activation of Glycogen synthase kinase-3&#x003b2; (GSK-3&#x003b2;) leads to tau hyperphosphorylation and resultant neurofibrillary tangles (NFT) toxicity in various neurodegenerative diseases. Early tau alterations may significantly lead to cognitive abnormalities (<xref rid="b0445" ref-type="bibr">Hochgr&#x000e4;fe et al., 2013</xref>). Cleavage of tau at Asp 421 causes pathogenic assembly of tau filaments more rapidly because cleaved tau has greater polymerization kinetics and acts as a nucleation center (<xref rid="b1020" ref-type="bibr">Yin and Kuret, 2006</xref>, <xref rid="b1070" ref-type="bibr">Zilka et al., 2006</xref>). There is a strong correlation between tau pathology and degree of dementia in AD patients (<xref rid="b0480" ref-type="bibr">Iqbal et al., 2005</xref>). Insulin receptor (IR) substrate molecules are phosphorylated by IR tyrosine kinase that leads to activation of phosphoinositide-3 kinase/Akt signaling (<xref rid="b0355" ref-type="bibr">Ghasemi et al., 2013</xref>). Activation of PI3k/Akt leads to phosphorylation of Ser9 of GSK3&#x003b2; and impairment of its kinase activity resulting in tau phosphorylation. Hence, insulin resistance/deficiency can induce aberrant activation of GSK-3&#x003b2; and hyperphosphorylation of tau in both T1DM and T2DM (<xref rid="b0860" ref-type="bibr">Salkovic-Petrisic et al., 2006</xref>, <xref rid="b0515" ref-type="bibr">Ke et al., 2009</xref>). Invitro studies demonstrate that short insulin treatment (&#x0003c;2&#x02013;3&#x000a0;min) results in quick and short hyperphosphorylation of tau. However, long (upto 60&#x000a0;min) exposure of neurons to insulin had significantly low phosphorylation of tau (<xref rid="b0605" ref-type="bibr">Lesort and Johnson, 2000</xref>, <xref rid="b0610" ref-type="bibr">Lesort et al., 1999</xref>). Though the mechanisms involved in diabetic induced tau phosphorylation is not fully understood, protein phosphatase 2A (PP2A) is involved in tau pathology. Surprisingly, PP2A is decreased in AD brains. Streptozotocin injection in a human tau expressing mice model resulted in tau hyperphosphorylation along with inhibition of PP2A, an important tau phosphatase. However, insulin injection significantly restored tau phosphorylation. Recently, Shentu et al demonstrated overexpression of cancerous inhibitor of PP2A (CIP2A) in AD brain. CIP2A-mediated PP2A inhibition not only drives tau/APP hyperphosphorylation but also enhanced A&#x003b2; production. PP2A inhibition leads to tau mislocalization to spines and dendrites followed by synaptic loss. This pathomechanism was also reflected in mice injected with AAV-CIP2A with impairments in cognitive deficits and long-term potentiation (<xref rid="b0890" ref-type="bibr">Shentu et al., 2018</xref>). Similarly, phosphorylation of endogenous specific inhibitor 2 (I<sub>2</sub><sup>PP2A</sup>), also known as SET (PP2A inhibitor) by casein kinase 2 caused tau hyperphosphorylation in neurons and animal models (<xref rid="b1030" ref-type="bibr">Zhang et al., 2018</xref>). Alzheimer patients have higher deteriorative risk of post-operative cognitive dysfunction after anesthesia. Anesthesia induced rapid and massive hyperphosphorylation of tau, inhibition of PP2A and prolonged hypothermia (<xref rid="b0805" ref-type="bibr">Planel et al., 2007</xref>). In addition, hypothermia after STZ injection had significant impact on tau hyperphosphorylation when compared to normothermic mice (<xref rid="b0365" ref-type="bibr">Gratuze et al., 2017</xref>). Hypothermia, an usual experimental outcome in diabetes leads to 80% increase in tau phosphorylation per degree celsius drop under 37&#x000a0;&#x000b0;C in mice (<xref rid="b0770" ref-type="bibr">Papon et al., 2013</xref>). Under normal condition, loss of tau causes impairment of hippocampal response to insulin and disrupts insulin mediated hypothalamic anorexigenic effect which demonstrated the importance of tau in brain signaling (<xref rid="b0680" ref-type="bibr">Marciniak et al., 2017</xref>). Phosphatase and tensin homolog (PTEN) and IRS-1 regulation plays a major role in tau mediated hippocampal response to insulin. Tau interacts with PTEN decreasing lipid phosphatase activity and blocks insulin signaling impairment. Thus, loss of tau also results in impaired insulin signaling in AD models (<xref rid="b0370" ref-type="bibr">Gratuze et al., 2018</xref>). In AD brain, more cytosolic levels of IRS-1 pS312 and pS616 correlate with NFTs but IRS-1 pS312 is confined to the nucleus in controls. Hence, IRS-1 phopho-species might have significant role in building up tau pathology in AD (<xref rid="b0735" ref-type="bibr">Moloney et al., 2010</xref>). Hence, not only tau hyperphosphorylation leads to NFTs and AD but loss of tau function also causes defective insulin signaling and AD pathology. Endocytic disturbance causes A&#x003b2; overload in the brain of T2DM model. Similarly, various AD risk genes such as ApoE, BIN1 (Bridging integrator 1), CLU (Clusterin), ABCA7 (ATP-binding cassette sub-family A member 7), CR1 (Complement C3b/C4b Receptor 1) and PICALM (Phosphatidylinositol Binding Clathrin Assembly Protein) are involved in endocytosis of tau in direct or indirect way. Hence, mutation in any of these genes might increase tau propagation and decrease tau endocytosis in the brain (<xref rid="b0085" ref-type="bibr">Avila et al., 2015</xref>). Recently, late-onset AD (LOAD) risk gene FRMD4A (FERM domain-containing 4A) was reported to regulate tau secretion via cytohesin-Arfb pathway, a pathway involved in presynaptic vesicle machinery and polarity signaling (<xref rid="b0955" ref-type="bibr">Uronen and Huttunen, 2016</xref>). However, more genetic studies are needed globally to understand if genetic risk factors could influence tau pathology in AD. Similar to A&#x003b2; focused AD therapies, various therapeutic strategies are emerging because tau pathology shows better correlation with cognitive deficits in AD patients than A&#x003b2;. These strategies include modulation of tau phosphorylation, targeting tau pos-translational modifications, microtubule stabilizers, tau aggregation inhibitors, anti-tau immunotherapy. These therapeutic strategies have been extensively reviewed recently by Miguel Medina (<xref rid="b0705" ref-type="bibr">Medina, 2018</xref>). Anti-diabetic drug metformin and its derivative phenformin enhanced PP2A activity and decreases tau hyperphosphorylation in primary neurons and tau transgenic mice model (<xref rid="b0530" ref-type="bibr">Kickstein et al., 2010</xref>). Oral administration of sodium selenate to tau transgenic mice also prevented tau pathology, activated PP2A and enhanced memory and functional recovery (<xref rid="b0245" ref-type="bibr">Corcoran et al., 2010</xref>). Phase II clinical study demonstrated the safety and tolerability of sodium selenate in mild-moderate AD patients. Clinical study using leuco-methylthioninium that directly inhibit tau protein assembly yielded positive results (<xref rid="b0880" ref-type="bibr">Seripa et al., 2016</xref>). However, new avenues targeting tauopathies are in pressing need to prevent and treat AD.</p></sec><sec id="s0035"><label>3.4</label><title>Inflammatory consequence in T2DM and AD</title><p id="p0045">Inflammation is an early pathological event that leads to neurodegeneration in AD (<xref rid="b0135" ref-type="bibr">Blum-Degena et al., 1995</xref>)and insulin resistance in T2DM (<xref rid="b0575" ref-type="bibr">Kubaszek et al., 2003</xref>). Post-mortem AD studies showed that neurofibrillary plaques (NPs) and NFTs are accompanied with inflammation which suggests a possible influence of inflammation in AD pathology. Adipose tissue inflammation is one of the important pathological hallmark of diabetes and obesity (<xref rid="b0755" ref-type="bibr">Ouchi et al., 2011</xref>, <xref rid="b0655" ref-type="bibr">Lumeng et al., 2007</xref>). Adipocyte derived proinflammatory factors such as cytokines, chemokines can cross Blood-Brain Barrier (BBB) mediating neuroinflammation (<xref rid="b0090" ref-type="bibr">Banks, 2005</xref>). Elevated A&#x003b2; levels in AD can trigger TNF-&#x003b1; levels by NIk-dependent pathway leading to deficit in synaptic plasticity and cognition (<xref rid="b0900" ref-type="bibr">Sims-Robinson et al., 2010</xref>, <xref rid="b0250" ref-type="bibr">Corona et al., 2012</xref>, <xref rid="b0190" ref-type="bibr">Carrero et al., 2012</xref>). In addition, inflammation suppresses incretin, an effector of reduced insulin resistance, whereas activation of incretin inhibits TNF-&#x003b1; production (<xref rid="b0225" ref-type="bibr">Clark and Vissel, 2014</xref>). Proinflammatory factors such as IL-1&#x003b2;, IL-6, Macrophage Migration factor, interferon gamma are present at the proximities of A&#x003b2; plaques, supporting their role in neuroinflammation (<xref rid="b0710" ref-type="bibr">Mehlhorn et al., 2000</xref>, <xref rid="b0275" ref-type="bibr">D'Andrea et al., 2001</xref>). Hyperglycemia induced neuroinflammation plays a major role in insulin resistance by feed-back inhibition of insulin receptor and causes mitochondrial dysfunction through feed-forward mechanisms (<xref rid="b0145" ref-type="bibr">Bonnard et al., 2008</xref>, <xref rid="b0210" ref-type="bibr">Cheng et al., 2010</xref>), This mechanism enhances expression of NF-&#x01d0b;B inducing kinase (NIk) which again compromises mitochondria function and subsequent insulin resistance (<xref rid="b0220" ref-type="bibr">Choudhary et al., 2011</xref>, <xref rid="b0885" ref-type="bibr">Sheng et al., 2012</xref>). Intracerebroventricular injection of STZ in rat hippocampus enhances ROS production and NF-&#x01d0b;B activation (<xref rid="b0640" ref-type="bibr">Locke and Anderson, 2011</xref>)which promotes apoptosis (<xref rid="b0490" ref-type="bibr">Jaeschke et al., 2004</xref>). In addition, NK-&#x01d0b;B regulates insulin sensitivity by modulating the expression of GLUT2 receptor (<xref rid="b0775" ref-type="bibr">Patel and Santani, 2009</xref>). Clinically, insulin resistance in T2DM is associated with enhanced levels of IL-6, C-reactive protein and &#x003b1;-1-antichymotrypsin (<xref rid="b0400" ref-type="bibr">Hak et al., 2001</xref>, <xref rid="b0960" ref-type="bibr">Van de Ree et al., 2003</xref>). Hence, chronic inflammation causes peripheral immune response which enhances cytokine production that crosses BBB causing neuroinflammation (<xref rid="b0695" ref-type="bibr">McGeer and McGeer, 2010</xref>). Advanced glycation end products (AGE) acts as a significant mediator of inflammation in both AD and insulin resistance in DM (<xref rid="b1005" ref-type="bibr">Yamagishi et al., 2012</xref>, <xref rid="b0950" ref-type="bibr">Unoki et al., 2007</xref>). Advanced glycation end products binds to receptor for advanced glycation end products (RAGE) to activate NF-&#x01d0b;B, a crucial factor for inflammation. AGE is also elevated in AD patients and they are localized in NPs, NFTs and in neurons and glia. Certain AGE&#x02019;s such as methyl-glyoxal-imidazolone-H1 (MG-H1) enhance the pro-inflammatory properties of A&#x003b2; or tau (<xref rid="b0910" ref-type="bibr">Srikanth et al., 2012</xref>, <xref rid="b0625" ref-type="bibr">Li et al., 2012</xref>). Clinically, MG-H1 levels in the circulation or brain are positively correlated with cognitive impairment in older patients (<xref rid="b0110" ref-type="bibr">Beeri et al., 2011</xref>, <xref rid="b0020" ref-type="bibr">Ahmed et al., 2005</xref>). Food-derived AGEs contribute largely to chronic diseases due to availability to thermally altered nutrients (<xref rid="b0560" ref-type="bibr">Koschinsky et al., 1997</xref>, <xref rid="b0130" ref-type="bibr">Birlouez-Aragon et al., 2010</xref>). Mice fed with MG derivatives increased body weight and systemic insulin resistance, increased brain amyloid deposits and gliosis with low survival factor sirtuin-1 (SIRT-1), which is involved in cellular longevity. Both in mice and humans, dietary MG levels and AGEs correlate with cognitive decline as measured by Mini Mental State Examination (<xref rid="b0155" ref-type="bibr">Cai et al., 2014</xref>). Hence, AGE acts as a modifiable risk factor for AD and metabolic syndrome by enhancing inflammation. Decrease in sirtuins enhances the risk of AD and insulin resistance which contributes to the interplay between AD and diabetes. Advanced glycation end products decreases SIRT-1 expression which results in insulin resistance, A&#x003b2; and tau phosphorylation (<xref rid="b0535" ref-type="bibr">Killick et al., 2009</xref>). Cross-sectional study involving Mexican adults (18&#x02013;35&#x000a0;years) showed that AGEs intake subjects were more likely to have impaired fasting glucose and metabolic syndrome regardless of sex, age and family history (<xref rid="b0715" ref-type="bibr">Mendoza-Herrera et al., 2018</xref>). Hence, blocking or inhibiting AGE expression might be an therapeutic target for AD drug development. Blocking RAGE in rats prevented tau hyperphosphorylation (<xref rid="b0660" ref-type="bibr">L&#x000fc;th et al., 2004</xref>). TTP488, an antagonist for RAGE was tested for its phase II clinical efficiency in people with mild to moderate AD. TTP488, at a dose of 5&#x000a0;mg demonstrated significant improvement on Alzheimer-disease-Assessment Scale-cognitive (ADAS-cog11), Clinical dementia rating Sum of Boxes (CDR-sb) and Alzhimer Diseas Cooperative Study-Activities of Daily Living scale (ADCS-ADL) compared to placebo (<xref rid="b0150" ref-type="bibr">Burstein et al., 2014</xref>). Therapeutically, TTP488 decreased amyloid uptake in brain and lowered glial inflammatory response. Currently, this drug is under Phase III clinical trials PPAR plays a major role in diabetes induced AD and it also modulates insulin-dependent gene expression in response to surface membrane signals (<xref rid="b0235" ref-type="bibr">Collino et al., 2008</xref>). Furthermore, PPAR has potent anti-inflammatory role owing to (1) reduced expression of PPAR in AD brains (<xref rid="b0295" ref-type="bibr">de la Monte and Wands, 2006</xref>);( 2) inhibition of PPAR-delta enhances neuroinflammation, A&#x003b2; 42 deposition and tau hyperphosphorylation (<xref rid="b0095" ref-type="bibr">Barroso et al., 2013</xref>). PPAR agonist such as thiazolidinedione class of drugs prevented A&#x003b2; induced secretion of pro-inflammatory cytokines such as TNF-&#x003b1; (<xref rid="b0240" ref-type="bibr">Combs et al., 2000</xref>). Aberrant TNF signaling and activation of JNK pathway plays a major role in peripheral insulin resistance (<xref rid="b0435" ref-type="bibr">Hirosumi et al., 2002</xref>). Moreover, activation of TNF/JNK pathway leads to endoplasmic reticulum stress, activates stress kinases (I&#x003ba;B kinase) and double-stranded RNA dependent protein kinases which are increased in AD brains (<xref rid="b0455" ref-type="bibr">Hoozemans et al., 2009</xref>, <xref rid="b0205" ref-type="bibr">Chang et al., 2002</xref>). Various reports demonstrate that inflammation and endoplasmic reticulum stress are key events in hypothalamic and peripheral insulin resistance in DM (<xref rid="b0305" ref-type="bibr">De Souza et al., 2005</xref>, <xref rid="b0820" ref-type="bibr">Purkayastha et al., 2011</xref>). Both I&#x003ba;B kinase and double-stranded RNA dependent protein kinases caused A&#x003b2; oligomer induced insulin receptor substrate 1 inhibition (<xref rid="b0140" ref-type="bibr">Bomfim et al., 2012</xref>). As discussed earlier, transgenic animal model (APP<sup>+</sup>/<italic>ob/ob</italic>) had elevated levels of RAGE in the blood and higher expression of TNF-&#x003b1; and IL-6 in the brain. Similarly, 3xTg AD mice raised with high fat diet had enhanced cerebrovascular inflammation and cognitive deficits, although no significant difference in NPs and NFTs were observed (<xref rid="b0545" ref-type="bibr">Knight et al., 2014</xref>). These studies demonstrate that pathological role of inflammation in diabetes induced AD. Hence, various groups are focusing on identifying pharmacological inhibitors of inflammation to improve insulin action. For example, salicylates inhibits inflammatory kinases and activates insulin signaling within the cell (<xref rid="b0540" ref-type="bibr">Kim et al., 2013</xref>). Targeting JNK using cell permeable peptide provokes insulin signaling in obese mice (<xref rid="b0600" ref-type="bibr">Lee et al., 2003</xref>). These studies demonstrate strong correlation between hyperglycemia, insulin resistance and inflammation which eventually leads to neurodegeneration in AD. Recent study by Estella et al demonstrate that not all <italic>ApoE-&#x003b5;4</italic> carriers develop AD but patients with <italic>ApoE-&#x003b5;4</italic> presence along with chronic low-grade neuroinflammation (C-protein measurement) had higher risk of AD (<xref rid="b0745" ref-type="bibr">Newcombe et al., 2018</xref>). In addition, presence of ApoE influences microglial response to amyloid plaque toxicity. Ulrich et al., 2018 demonstrated that presence of ApoE not only affected amyloid plaque clearance but also induced aggregation of monomeric A&#x003b2; and enhanced fibrillary plaque associated microgliosis. Hence, presence of ApoE directly facilitates amyloid plaque formation and activates microgliosis resulting in neuroinflammation. In addition to the inflammatory role, microglia interacts with amyloid plaque, thereby reducing early AD pathology by phagocytic actions. However, presence of ApoE significantly reduced the expression of triggering receptor expressed on myeloid cells 2 (TREM2) which regulates microglial plaque coverage and subsequent phagocytosis (<xref rid="b0920" ref-type="bibr">Stephen et al., 2019</xref>). Similarly, ApoE activation transforms homeostatic microglia to activated state after phagocytosis of apoptotic neurons. However, targeting ApoE signaling reverses microglia to homeostatic state (<xref rid="b0565" ref-type="bibr">Krasemann et al., 2017</xref>). Recently, Aburawi et al demonstrated that subclinical inflammation and endothelial dysfunction were common in young diabetic Emirati patients in UAE. Obesity and dyslipidemia were associated with higher levels of TNF-&#x003b1;, IL-6 and lower adiponectin (<xref rid="b0005" ref-type="bibr">Aburawi et al., 2016</xref>). TNF-&#x003b1; decreases peripheral intake of glucose in response to insulin that causes insulin resistance in DM and obesity (<xref rid="b0815" ref-type="bibr">Priyadarshini et al., 2012</xref>). Similarly, diabetic UAE citizens had enhanced inflammatory markers with decreased antioxidants with increased body-mass index (BMI) and waist circumference (<xref rid="b0345" ref-type="bibr">Gariballa et al., 2014</xref>). Hence, chronic low grade inflammation may play pathological role in DM. White blood cells is an important marker of activated immune system. Vozarova et al demonstrated that high WBC count is an independent predictor of insulin impairment and T2DM development in Pima Indian population. Other inflammatory markers such as orosomucoid acid and sialic acid were also associated with later development of T2DM (<xref rid="b0975" ref-type="bibr">Vozarova et al., 2002</xref>, <xref rid="b0875" ref-type="bibr">Schmidt et al., 1999</xref>). Metabolic stress such as inflammation and excess nutrients enhance insulin resistance and obesity by increasing expression of mitogen-activated protein kinases (MAPK), c-Jun NH-<sub>2</sub>-terminal kinase (JNK) and p38 MAPK. Inflammation also induces the expression of dual-specificity phosphatase-1 (DUSP-1) or mitogen-activated protein kinase phosphatase (MKP-1) that inactivates JNK and p38 MAPK. In skeletal muscle, a major tissue involved in glucose metabolism, MPK-1 is upregulated in obese humans and in high-fat diet fed mice. Whereas, knock-down of MKP-1 enhanced the expression of p38 MAPK and JNK along with resistance to diet-induced obesity (<xref rid="b0595" ref-type="bibr">Lawan et al., 2018</xref>). In cardiovascular diseases (CVD), MPK-1 is shown to be higher in circulating blood cells even after conventional treatments (<xref rid="b0510" ref-type="bibr">Kapoor et al., 2014</xref>). In a clinical study involving 207 Arab adults extracted from Kuwait Diabetes Epidemiology Program (KDEP), Khadir et al demonstrated that DUSP-1/MKP-1 and high-sensitivity CRP (hsCRP) were higher and they are independently associated with CVD in Arab population in addition to statin treatment (<xref rid="b0520" ref-type="bibr">Khadir et al., 2018</xref>). Hence, DUSP-1 might be one of the profounding inflammatory factor involved in insulin resistance and obesity in Arab population. Various reports suggest that there is an intricate association between inflammation and mitochondria dysfunction in promoting neurodegeneration (<xref rid="b0965" ref-type="bibr">van Horssen et al., 2017</xref>, <xref rid="b0555" ref-type="bibr">Kolmychkova et al., 2016</xref>). Here we provide an overview on how mitochondrial deficits and oxidative stress mediates DM and AD.</p></sec><sec id="s0040"><label>3.5</label><title>Mitochondrial impairment and oxidative stress in T2DM and AD</title><p id="p0050">Mitochondrial dysfunction, oxidative stress and subsequent antioxidant decline are key pathological players that precede or accompany AD and T2DM (<xref rid="b0740" ref-type="bibr">Moreira et al., 2007</xref>). Mitochondria has decisive role in ATP production, buffering of cytoplasmic Ca<sup>2+</sup>, metabolism of ROS and apoptosis (<xref rid="b0685" ref-type="bibr">Mattson et al., 2008</xref>). Specifically in the neurons, mitochondria are essential to maintain membrane ion gradients, synaptic plasticity and neurotransmission (<xref rid="b0330" ref-type="bibr">Fontan-Lozano et al., 2008</xref>). Changes in shape of mitochondria perturbs synaptic transmission in presynaptic neurons. For example torus shaped (donut-shaped) mitochondria represents oxidative stress and responsible for cognitive decline in old monkey models (<xref rid="b0405" ref-type="bibr">Hara et al., 2014</xref>). In diabetic brain, both A&#x003b2; and tau can cause mitochondrial alterations leading to neuronal energy deficit, synaptic disturbance and neurodegeneration (<xref rid="b0030" ref-type="bibr">Akhter et al., 2017</xref>). Dendritic spines of excitatory glutamatergic synapses (NMDA receptor) possess more metabolically active mitochondria that results in high Ca<sup>2+</sup> influx which promotes neuronal death (<xref rid="b0120" ref-type="bibr">Bezprozvanny and Mattson, 2008</xref>). In addition, A&#x003b2; oligomers stimulate excitatory NMDA receptors that leads to Ca<sup>2+</sup> dependent mitochondrial dysfunction and ROS production (<xref rid="b0280" ref-type="bibr">De Felice et al., 2007</xref>). Insulin signaling plays a major role in protecting mitochondria. Insulin signaling stimulation protects LAN5 (neuroblastoma) cells against A&#x003b2; induced oxidative stress by activating Akt pathway and inhibiting expression of pro-apoptotic transcription factors and maintaining mitochondrial membrane potential (<xref rid="b0790" ref-type="bibr">Picone et al., 2011</xref>). Hence, there is a close relationship between insulin signaling, mitochondrial oxidative stress and neurodegeneration. In the periphery, physiological stimuli such as insulin facilitates ROS generation, by inhibiting protein phosphatases (<xref rid="b0645" ref-type="bibr">Loh et al., 2009</xref>). High fat diet causes mitochondrial ROS production in skeletal muscles that causes insulin resistance in T2DM (<xref rid="b0075" ref-type="bibr">Anderson et al., 2009</xref>). Apart from cellular factors, mutations in mitochondrial DNA are associated with DM. Few mutations in mitochondrial DNA such as A3243G in the mitochondrial DNA-encoded transfer RNA (tRNA) gene are closely associated with diabetes. Carriers of A3243G showed marked decrease in insulin secretion when compared to non-carriers which might be due to decrease in cytosol ADP/ATP levels resulting in resetting glucose sensor such as maturity-onset diabetes of the young (MODY)-2 with glucokinase mutation in pancreatic &#x003b2; cell (<xref rid="b0665" ref-type="bibr">Maassen et al., 2004</xref>). Oxidative stress and antioxidant activity was evaluated in serum samples collected from Japanese patients carrying A3243G mutation. Mean diacron-reactive oxygen metabolites (d-ROMs), a marker for oxidative stress was significantly higher in carriers than controls concluding that carriers of A3243G mutation is always exposed to constant oxidative stress (<xref rid="b0465" ref-type="bibr">Ikawa et al., 2012</xref>). Mitochondrial proteome study using mitochondria isolated from skeletal muscle of T2DM patients resulted in 335 differentially expressed proteins (DEPs) between diabetic and non-diabetic groups. The study concluded that two DEPs (NDUFS3 and COX2) for downregulated oxidative phosphorylation and three DEPs (CALR, SORT and RAB1A) for upregulated calcium and protein transport representing mitochondria-associated ER membrane functions could be used as a potential protein profile for dysregulation of mitochondrial function in T2DM (<xref rid="b0200" ref-type="bibr">Chae et al., 2018</xref>). Interestingly, point mutation in mitochondrial DNA nt3243 in Japanese women resulted in AD brain pathology. During the last ten years, the women was diagnosed with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS). Post-mortem studies showed presence of senile plaques through the brain, mostly in frontal and temporal lobes and NFTs in parahippocampal gyrus (<xref rid="b0505" ref-type="bibr">Kaido et al., 1996</xref>). However, mutations in codons 693, 713 and 717 of &#x003b2;-amyloid precursor protein were not found. This study proved a possible link between mitochondria DNA abnormality and AD like pathology. Nonetheless, the presence of A3243 mutation as a risk factor for diabetes or AD in Arab population is not yet reported. Amount of ROS produced by mitochondria directly contributes to apoptosis and since pancreatic-&#x003b2; cells have poor regeneration capacity after cell loss, insulin deficiency occurs. Similarly, inhibition of insulin receptor by A&#x003b2; oligomers causes NMDA receptor dysregulation, oxidative stress and impaired insulin signaling in hippocampal neurons. Oxidative changes in mitochondrial proteins, lipids and nucleic acids enhances ROS production, A&#x003b2; accumulation and tau phosphorylation (<xref rid="b0935" ref-type="bibr">Swerdlow and Khan, 2004</xref>). Intracerebroventricular injection of STZ causes mitochondrial dysfunction (<xref rid="b0995" ref-type="bibr">Xu et al., 2003</xref>), impairs insulin/IGF signaling through PI3 kinase-Akt leading to enhanced GSK-3&#x003b2; activity (<xref rid="b0300" ref-type="bibr">de la Monte and Wands, 2008</xref>). As mentioned earlier, high GSK-3&#x003b2; activity leads to tau hyperphosphorylation and neuronal death. In addition of hyperglycemia, hypoglycemia also leads to mitochondria deficits (<xref rid="b0175" ref-type="bibr">Cardoso et al., 2013</xref>)and cognitive decline (<xref rid="b0925" ref-type="bibr">Strachan et al., 2000</xref>). Insulin induced acute hypoglycemia impairs antioxidant defense, oxidative damage and release of excitatory amino acids by cortical neurons (<xref rid="b0160" ref-type="bibr">Cardoso et al., 2010</xref>, <xref rid="b0165" ref-type="bibr">Cardoso et al., 2011</xref>). Long-term hyperglycemia and recurrent hypoglycemia impairs antioxidant defense in brain hippocampal and cortical mitochondria resulting in oxidative stress (<xref rid="b0170" ref-type="bibr">Cardoso et al., 2013</xref>). A retrospective population study using Western Australian hospital inpatient, mental health outpatient, and death records showed that patients with cognitive impairment or dementia were likely to be admitted for hypoglycemia (<xref rid="b1075" ref-type="bibr">Zilkens et al., 2013</xref>). Hence, repeated hypoglycemia leads to cognitive decline and acts as a major contributor of dementia. Mitochondrial uncoupling proteins (UPs) regulate ROS production and it acts as a key defense mechanisms against brain damage (<xref rid="b0180" ref-type="bibr">Cardoso et al., 2015</xref>). Pharmacological inhibition of UP2 aggravates glucose mediated neuronal damage, mitochondrial dysfunction and enhances oxidative stress (<xref rid="b0185" ref-type="bibr">Cardoso et al., 2018</xref>). Zucker diabetic fatty rat model demonstrated mitochondrial dysfunction and oxidative stress (<xref rid="b0825" ref-type="bibr">Raza et al., 2015</xref>). Similarly, Goto-Kakizaki non-obese T2DM rat model also showed age-dependent redox perturbation which enhances neurodegenerative events (<xref rid="b0195" ref-type="bibr">Carvalho et al., 2014</xref>). These studies suggest that metabolic disturbances associated with DM causes oxidative stress and mitochondrial deficits as seen in AD. Huang et al demonstrated that aberrant mitochondrial morphology, impaired mitochondrial complex I activity, decline in ATP production are seen in obese T2DM mice model. These alterations were due to impaired mitochondrial fusion and fission through GSK-3&#x003b2;/Drp-1 (dynamin-related protein 1) mechanism. Further, supporting the link between metabolic and cognitive diseases, Akhtar et al demonstrated that amyloid beta oligomers and high glucose concentration causes S-nitrosylation of Drp-1 and IDE as well as hyperactivating mitochondria fission resulting in dysfunctional synaptic plasticity (<xref rid="b0025" ref-type="bibr">Akhtar et al., 2016</xref>). Intracerebroventricular (icv) injection of sub-diabetogenic STZ dose caused mitochondria abnormalities by decreasing mitochondria membrane potential, repolarization levels, respiratory state 3, ATP content and increase in lag phase of repolarization. Also, icv injection decreased pyruvate and &#x003b1;-ketoglutarate dehydrogenase, cytochrome <italic>c</italic> oxidase activities and impaired antioxidant defense mechanisms (<xref rid="b0255" ref-type="bibr">Correia et al., 2013</xref>). Though these reports demonstrate the pathological relationship between insulin resistance and mitochondrial dysfunction in diabetes induced AD, the exact molecular mechanisms through which mitochondrial dysfunction causes diabetes induced AD is still not clear. Thus, anti-diabetic drug might have profound effect on mitochondria deficit. Anti-diabetic drugs such as metformin (<xref rid="b0795" ref-type="bibr">Pintana et al., 2012</xref>)and dipeptidyl-peptidase-4 inhibitors (<xref rid="b0800" ref-type="bibr">Pintana et al., 2013</xref>)prevented mitochondrial deficits and cognitive decline in high fat insulin resistance rats. Similarly, GLP-1 analogues prevented tau phosphorylation and apoptosis, increased brain insulin and insulin like growth factor 1 levels in T2DM rats (<xref rid="b1000" ref-type="bibr">Xu et al., 2015</xref>, <xref rid="b1010" ref-type="bibr">Yang et al., 2016</xref>). Few mitochondria enhancing drugs such as MP-101, rasagiline and oxaloacetate are currently under clinical trials for AD treatment (<xref rid="b0265" ref-type="bibr">Cummings et al., 2018</xref>).</p><p id="p0055">Overall, impairment of downstream insulin signaling by either A&#x003b2; oligomers or ApoE protein causes mitochondrial dysfunction, oxidative stress, enhanced expression of advanced glycation end products (AGEs) and inflammation in AD. Accumulation of A&#x003b2; oligomers in both pancreas and brain represent the ability of A&#x003b2; oligomers to cross seed between pancreas and brain promoting cellular/neuronal dysfunction in both T2DM and AD. Both A&#x003b2; oligomers and ApoE proteins blocks insulin receptors resulting in deficits in downstream signaling pathways such as PI3K and Akt. These deficits reduces glucose metabolism, enhances oxidative stress and alters JNK activity. Under normal physiological conditions, insulin signaling pathway reduces excess A&#x003b2; through insulin degrading enzyme (IDE) and by inhibiting translation of BACE and APP gene that results in less cleavage of BACE1 and APP. Moreover, insulin signaling pathway reduces GSK-3&#x003b2; phosphorylation which in turn reduces neurofibrillary tangle formation and subsequent neuronal death. Intracellular accumulation of A&#x003b2; oligomers is prevented by trafficking A&#x003b2; oligomers from golgi and <italic>trans</italic>-golgi network to extracellular milieu. A&#x003b2; oligomers also causes activation of microglia, production of pro-inflammatory factors (primarily TNF-&#x003b1;) and initiating downstream JNF pathway that again blocks brain&#x02019;s insulin receptors. In addition, oxidative stress causes activation of AGEs which inturn causes NF-&#x01d0b;B activation, tau hyperphosphorylation and A&#x003b2; oligomerization. Apart from A&#x003b2; oligomers, ApoE also binds to insulin receptor blocking downstream signaling. In addition of proteolytic cleavage of A&#x003b2; oligomers by IDE, A&#x003b2; oligomers are also degraded by receptor mediated uptake by glia and neurons. Primarily ApoE is synthesized in the glia, lapidated by ABCA1 transporter forming lipoprotein particles. Soluble A&#x003b2; binds to lapidated ApoE and facilitates neuronal uptake of A&#x003b2; through LRP1, LDLR and HSPG cell surface receptors where A&#x003b2; is degraded by lysosomal pathway. However, ApoE modification (ApoE-&#x003b5;4) or ABCA1 deficiency impairs this process causing intracellular accumulation of A&#x003b2; oligomers and neuronal death (<xref rid="f0005" ref-type="fig">Fig. 1</xref>).<fig id="f0005"><label>Fig. 1</label><caption><p>Overview of different pathomechanisms linking DM and AD. Amyloid beta oligomers and ApoE mutation causes dysregulation of downstream insulin signaling pathway resulting in oxidative stress, mitochondrial dysfunction, AGE expression and inflammation. Cross-seeding of A&#x003b2; oligomers between the pancreas and the brain promotes cellular dysfunction in both T2DM and AD. A&#x003b2; oligomers and ApoE protein blocks insulin receptors resulting in impairment of PI3K and Akt pathways and activates microglia mediated JNK downstream pathway. Further, dysregulation of insulin signaling pathway enhances A&#x003b2; production due to translation of BACE and APP, increases GSK-3&#x003b2; phosphorylation resulting in NFT formation and neuronal death. In addition, A&#x003b2; oligomers are degraded by lysosomal pathway. However, ApoE mutation impairs lysosomal degradation resulting in intracellular accumulation of A&#x003b2; and cell death.</p></caption><graphic xlink:href="gr1"/></fig></p></sec></sec><sec id="s0045"><label>4</label><title>Conclusion</title><p id="p0060">Traditionally, AD and DM were thought to be independent disorders. However, various clinical and pre-clinical studies have demonstrated that AD and DM share common pathological mechanisms. However, DM cannot be assumed to be sufficient to cause AD but could act as a cofactor in AD progression due to selective impairments in insulin signaling accompanied by significant upregulation of A&#x003b2; aggregation, tau hyperphosphorylation, inflammation, oxidative stress and mitochondrial dysfunction. Due to shared pathology, it has been suggested that anti-diabetic drugs may have therapeutic potential in treating AD and currently tested in clinical trials. Some anti-diabetic drugs were already reported to be beneficial against few hallmark AD pathology and they also promoted neurogenesis. Although, these drugs showed promising results, precise knowledge on common pathomechanisms between DM and AD, molecular action of drugs both centrally and peripherally, influence of demographic changes and genetic mutations on AD progression are urgently needed for diagnostic and therapeutic purposes. Particularly, in the MENA region, the influence of genetic mutations in AD risk genes such as ACE, DCP1, FTO, TCF7L2, PPAR-&#x003b3;2, ApoE, BIN1, CLU, ABCA7, CR1, PICALM, FRMD4A that plays a major role in diabetes, insulin resistance, obesity and AD progression needs to be screened to prevent AD at the pre-clinical stage. In addition, increase in AD awareness, diagnosis and treatment strategies and population based studies are much needed to avert DM induced dementia in high-risk population.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0065">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Aburawi</surname><given-names>E.H.</given-names></name><name><surname>AlKaabi</surname><given-names>J.</given-names></name><name><surname>Zoubeidi</surname><given-names>T.</given-names></name><name><surname>Shehab</surname><given-names>A.</given-names></name><name><surname>Lessan</surname><given-names>N.</given-names></name><name><surname>Al Essa</surname><given-names>A.</given-names></name></person-group><article-title>Subclinical inflammation and endothelial dysfunction in young patients with diabetes: a study from United Arab Emirates</article-title><source>PLoS ONE</source><volume>11</volume><issue>7</issue><year>2016</year><object-id pub-id-type="publisher-id">e0159808</object-id></element-citation></ref><ref id="b0010"><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Abyad</surname><given-names>A.</given-names></name></person-group><article-title>Alzheimer&#x02019;s the road ahead in the middle east</article-title><source>J Alzheimers Dis Parkinsonism</source><volume>6</volume><issue>241</issue><year>2016</year><comment>pp. 2161&#x02013;0460.1000241</comment></element-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Aguado</surname><given-names>B.</given-names></name><name><surname>Campbell</surname><given-names>R.D.</given-names></name></person-group><article-title>Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex</article-title><source>J. Biol. Chem.</source><volume>273</volume><issue>7</issue><year>1998</year><fpage>4096</fpage><lpage>4105</lpage><pub-id pub-id-type="pmid">9461603</pub-id></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>N.</given-names></name><name><surname>Ahmed</surname><given-names>U.</given-names></name><name><surname>Thornalley</surname><given-names>P.J.</given-names></name><name><surname>Hager</surname><given-names>K.</given-names></name><name><surname>Fleischer</surname><given-names>G.</given-names></name><name><surname>M&#x000fc;nch</surname><given-names>G.</given-names></name></person-group><article-title>Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment</article-title><source>J. Neurochem.</source><volume>92</volume><issue>2</issue><year>2005</year><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">15663474</pub-id></element-citation></ref><ref id="b0025"><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>M.W.</given-names></name><name><surname>Sanz-Blasco</surname><given-names>S.</given-names></name><name><surname>Dolatabadi</surname><given-names>N.</given-names></name><name><surname>Parker</surname><given-names>J.</given-names></name><name><surname>Chon</surname><given-names>K.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name></person-group><article-title>Elevated glucose and oligomeric beta-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation</article-title><source>Nat. Commun.</source><volume>7</volume><year>2016</year><fpage>10242</fpage><pub-id pub-id-type="pmid">26743041</pub-id></element-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Akhter</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Yan</surname><given-names>S.F.</given-names></name><name><surname>Yan</surname><given-names>S.S.</given-names></name></person-group><article-title>Mitochondrial perturbation in Alzheimer's disease and diabetes</article-title><source>Prog. Mol. Biol. Transl. Sci.</source><volume>146</volume><year>2017</year><fpage>341</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">28253990</pub-id></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Akter</surname><given-names>K.</given-names></name><name><surname>Lanza</surname><given-names>E.A.</given-names></name><name><surname>Martin</surname><given-names>S.A.</given-names></name><name><surname>Myronyuk</surname><given-names>N.</given-names></name><name><surname>Rua</surname><given-names>M.</given-names></name><name><surname>Raffa</surname><given-names>R.B.</given-names></name></person-group><article-title>Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?</article-title><source>Br. J. Clin. Pharmacol.</source><volume>71</volume><issue>3</issue><year>2011</year><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">21284695</pub-id></element-citation></ref><ref id="b0040"><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Al Amiri</surname><given-names>E.</given-names></name><name><surname>Abdullatif</surname><given-names>M.</given-names></name><name><surname>Abdulle</surname><given-names>A.</given-names></name><name><surname>Al Bitar</surname><given-names>N.</given-names></name><name><surname>Afandi</surname><given-names>E.Z.</given-names></name><name><surname>Parish</surname><given-names>M.</given-names></name></person-group><article-title>The prevalence, risk factors, and screening measure for prediabetes and diabetes among Emirati overweight/obese children and adolescents</article-title><source>BMC Public Health</source><volume>15</volume><issue>1</issue><year>2015</year><fpage>1298</fpage><pub-id pub-id-type="pmid">26704130</pub-id></element-citation></ref><ref id="b0045"><mixed-citation publication-type="other" id="h0045">Alaama, T., Basheikh, M., Khiyami, A., Mutwalli, M., Batawi, S., Watfa, G., 2016. Diabetes status is associated with poor cognitive performace in Saudi population at high metabolic risk.</mixed-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Alhyas</surname><given-names>L.</given-names></name><name><surname>McKay</surname><given-names>A.</given-names></name><name><surname>Balasanthiran</surname><given-names>A.</given-names></name><name><surname>Majeed</surname><given-names>A.</given-names></name></person-group><article-title>Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic review</article-title><source>JRSM Short Rep.</source><volume>2</volume><issue>7</issue><year>2011</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">21286224</pub-id></element-citation></ref><ref id="b0055"><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Alhyas</surname><given-names>L.</given-names></name><name><surname>McKay</surname><given-names>A.</given-names></name><name><surname>Majeed</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: a systematic review</article-title><source>PLoS ONE</source><volume>7</volume><issue>8</issue><year>2012</year><object-id pub-id-type="publisher-id">e40948</object-id></element-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Al-Safar</surname><given-names>H.</given-names></name><name><surname>Hassoun</surname><given-names>A.</given-names></name><name><surname>Almazrouei</surname><given-names>S.</given-names></name><name><surname>Kamal</surname><given-names>W.</given-names></name><name><surname>Afandi</surname><given-names>B.</given-names></name><name><surname>Rais</surname><given-names>N.</given-names></name></person-group><article-title>Association of the genetic polymorphisms in transcription factor 7-like 2 and peroxisome proliferator-activated receptors-&#x003b3;2 with type 2 diabetes mellitus and its interaction with obesity status in Emirati Population</article-title><source>J. Diabetes Res.</source><volume>2015</volume><year>2015</year></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Al-Saikhan</surname><given-names>F.I.</given-names></name><name><surname>Abd-Elaziz</surname><given-names>M.A.</given-names></name><name><surname>Ashour</surname><given-names>R.H.</given-names></name></person-group><article-title>Association between risk of type 2 diabetes mellitus and angiotensin-converting enzyme insertion/deletion gene polymorphisms in a Saudi Arabian population</article-title><source>Biomed. Rep.</source><volume>7</volume><issue>1</issue><year>2017</year><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">28685061</pub-id></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Alsmadi</surname><given-names>O.</given-names></name><name><surname>Al-Rubeaan</surname><given-names>K.</given-names></name><name><surname>Mohamed</surname><given-names>G.</given-names></name><name><surname>Alkayal</surname><given-names>F.</given-names></name><name><surname>Al-Saud</surname><given-names>H.</given-names></name><name><surname>Al-Saud</surname><given-names>N.A.</given-names></name></person-group><article-title>Weak or no association of TCF7L2 variants with Type 2 diabetes risk in an Arab population</article-title><source>BMC Med. Genet.</source><volume>9</volume><issue>1</issue><year>2008</year><fpage>72</fpage><pub-id pub-id-type="pmid">18655717</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>E.J.</given-names></name><name><surname>Lustig</surname><given-names>M.E.</given-names></name><name><surname>Boyle</surname><given-names>K.E.</given-names></name><name><surname>Woodlief</surname><given-names>T.L.</given-names></name><name><surname>Kane</surname><given-names>D.A.</given-names></name><name><surname>Lin</surname><given-names>C.T.</given-names></name></person-group><article-title>Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans</article-title><source>J Clin Invest.</source><volume>119</volume><issue>3</issue><year>2009</year><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">19188683</pub-id></element-citation></ref><ref id="b0080"><element-citation publication-type="book" id="h0080"><person-group person-group-type="author"><name><surname>Atlas</surname><given-names>D.</given-names></name></person-group><chapter-title>International Diabetes Federation. IDF Diabetes Atlas</chapter-title><edition>seventh ed.</edition><year>2015</year><publisher-name>International Diabetes Federation</publisher-name><publisher-loc>Brussels, Belgium</publisher-loc></element-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Avila</surname><given-names>J.</given-names></name><name><surname>G&#x000f3;mez-Ramos</surname><given-names>A.</given-names></name><name><surname>Bol&#x000f3;s</surname><given-names>M.</given-names></name></person-group><article-title>AD genetic risk factors and tau spreading</article-title><source>Front. Aging Neurosci.</source><volume>7</volume><year>2015</year><fpage>99</fpage><pub-id pub-id-type="pmid">26052285</pub-id></element-citation></ref><ref id="b0090"><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W.A.</given-names></name></person-group><article-title>Blood-brain barrier transport of cytokines: a mechanism for neuropathology</article-title><source>Curr. Pharm. Des.</source><volume>11</volume><issue>8</issue><year>2005</year><fpage>973</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">15777248</pub-id></element-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>E.</given-names></name><name><surname>del Valle</surname><given-names>J.</given-names></name><name><surname>Porquet</surname><given-names>D.</given-names></name><name><surname>Santos</surname><given-names>A.M.V.</given-names></name><name><surname>Salvad&#x000f3;</surname><given-names>L.</given-names></name><name><surname>Rodr&#x000ed;guez-Rodr&#x000ed;guez</surname><given-names>R.</given-names></name></person-group><article-title>Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPAR&#x003b2;/&#x003b4;-null mice</article-title><source>Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.</source><volume>1832</volume><issue>8</issue><year>2013</year><fpage>1241</fpage><lpage>1248</lpage></element-citation></ref><ref id="b0100"><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Baynouna</surname><given-names>L.M.</given-names></name><name><surname>Revel</surname><given-names>A.D.</given-names></name><name><surname>Nagelkerke</surname><given-names>N.J.</given-names></name><name><surname>Jaber</surname><given-names>T.M.</given-names></name><name><surname>Omar</surname><given-names>A.O.</given-names></name><name><surname>Ahmed</surname><given-names>N.M.</given-names></name></person-group><article-title>High prevalence of the cardiovascular risk factors in Al-Ain, United Arab Emirates. An emerging health care priority</article-title><source>Saudi Med. J.</source><volume>29</volume><issue>8</issue><year>2008</year><fpage>1173</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">18690314</pub-id></element-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Beeler</surname><given-names>N.</given-names></name><name><surname>Riederer</surname><given-names>B.M.</given-names></name><name><surname>Waeber</surname><given-names>G.</given-names></name><name><surname>Abderrahmani</surname><given-names>A.</given-names></name></person-group><article-title>Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes</article-title><source>Brain Res. Bull.</source><volume>80</volume><issue>4&#x02013;5</issue><year>2009</year><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">19616077</pub-id></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Beeri</surname><given-names>M.S.</given-names></name><name><surname>Moshier</surname><given-names>E.</given-names></name><name><surname>Schmeidler</surname><given-names>J.</given-names></name><name><surname>Godbold</surname><given-names>J.</given-names></name><name><surname>Uribarri</surname><given-names>J.</given-names></name><name><surname>Reddy</surname><given-names>S.</given-names></name></person-group><article-title>Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals</article-title><source>Mech. Ageing Dev.</source><volume>132</volume><issue>11&#x02013;12</issue><year>2011</year><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">22079406</pub-id></element-citation></ref><ref id="b0115"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Berkowitz</surname><given-names>C.L.</given-names></name><name><surname>Mosconi</surname><given-names>L.</given-names></name><name><surname>Rahman</surname><given-names>A.</given-names></name><name><surname>Scheyer</surname><given-names>O.</given-names></name><name><surname>Hristov</surname><given-names>H.</given-names></name><name><surname>Isaacson</surname><given-names>R.S.</given-names></name></person-group><article-title>Clinical application of APOE in Alzheimer's prevention: a precision medicine approach</article-title><source>J. Prevent. Alzheimer's Dis.</source><volume>5</volume><issue>4</issue><year>2018</year><fpage>245</fpage><lpage>252</lpage></element-citation></ref><ref id="b0120"><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Bezprozvanny</surname><given-names>I.</given-names></name><name><surname>Mattson</surname><given-names>M.P.</given-names></name></person-group><article-title>Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease</article-title><source>Trends Neurosci.</source><volume>31</volume><issue>9</issue><year>2008</year><fpage>454</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">18675468</pub-id></element-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Bhalla</surname><given-names>D.</given-names></name><name><surname>Lotfalinezhad</surname><given-names>E.</given-names></name><name><surname>Amini</surname><given-names>F.</given-names></name><name><surname>Salmannejad</surname><given-names>M.</given-names></name><name><surname>Reza Borhani Nezhad</surname><given-names>V.</given-names></name><name><surname>Rezai Kooshalshah</surname><given-names>S.F.</given-names></name></person-group><article-title>Incidence and risk profile of dementia in the regions of middle east and North Africa</article-title><source>Neuroepidemiology</source><volume>50</volume><issue>3&#x02013;4</issue><year>2018</year><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">29550815</pub-id></element-citation></ref><ref id="b0130"><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Birlouez-Aragon</surname><given-names>I.</given-names></name><name><surname>Saavedra</surname><given-names>G.</given-names></name><name><surname>Tessier</surname><given-names>F.J.</given-names></name><name><surname>Galinier</surname><given-names>A.</given-names></name><name><surname>Ait-Ameur</surname><given-names>L.</given-names></name><name><surname>Lacoste</surname><given-names>F.</given-names></name></person-group><article-title>A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases</article-title><source>Am. J. Clin. Nutrit.</source><volume>91</volume><issue>5</issue><year>2010</year><fpage>1220</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">20335546</pub-id></element-citation></ref><ref id="b0135"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Blum-Degena</surname><given-names>D.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>T.</given-names></name><name><surname>Kuhn</surname><given-names>W.</given-names></name><name><surname>Gerlach</surname><given-names>M.</given-names></name><name><surname>Przuntek</surname><given-names>H.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name></person-group><article-title>Interleukin-1&#x003b2; and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients</article-title><source>Neurosci. Lett.</source><volume>202</volume><issue>1&#x02013;2</issue><year>1995</year><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8787820</pub-id></element-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Bomfim</surname><given-names>T.R.</given-names></name><name><surname>Forny-Germano</surname><given-names>L.</given-names></name><name><surname>Sathler</surname><given-names>L.B.</given-names></name><name><surname>Brito-Moreira</surname><given-names>J.</given-names></name><name><surname>Houzel</surname><given-names>J.-C.</given-names></name><name><surname>Decker</surname><given-names>H.</given-names></name></person-group><article-title>An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer&#x02019;s disease&#x02013;associated A&#x003b2; oligomers</article-title><source>J. Clin. Investig.</source><volume>122</volume><issue>4</issue><year>2012</year><fpage>1339</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">22476196</pub-id></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Bonnard</surname><given-names>C.</given-names></name><name><surname>Durand</surname><given-names>A.</given-names></name><name><surname>Peyrol</surname><given-names>S.</given-names></name><name><surname>Chanseaume</surname><given-names>E.</given-names></name><name><surname>Chauvin</surname><given-names>M.-A.</given-names></name><name><surname>Morio</surname><given-names>B.</given-names></name></person-group><article-title>Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice</article-title><source>J. Clin. Investig.</source><volume>118</volume><issue>2</issue><year>2008</year><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">18188455</pub-id></element-citation></ref><ref id="b0150"><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>A.H.</given-names></name><name><surname>Grimes</surname><given-names>I.</given-names></name><name><surname>Galasko</surname><given-names>D.R.</given-names></name><name><surname>Aisen</surname><given-names>P.S.</given-names></name><name><surname>Sabbagh</surname><given-names>M.</given-names></name></person-group><article-title>Mjalli AMM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease</article-title><source>BMC Neurol.</source><volume>14</volume><year>2014</year><fpage>12-</fpage><pub-id pub-id-type="pmid">24423155</pub-id></element-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W.</given-names></name><name><surname>Uribarri</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Swamy</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name></person-group><article-title>Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>111</volume><issue>13</issue><year>2014</year><fpage>4940</fpage><lpage>4945</lpage><pub-id pub-id-type="pmid">24567379</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Santos</surname><given-names>M.S.</given-names></name><name><surname>Seica</surname><given-names>R.</given-names></name><name><surname>Moreira</surname><given-names>P.I.</given-names></name></person-group><article-title>Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia</article-title><source>BBA</source><volume>1802</volume><issue>11</issue><year>2010</year><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">20620209</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Carvalho</surname><given-names>C.</given-names></name><name><surname>Santos</surname><given-names>R.</given-names></name><name><surname>Correia</surname><given-names>S.</given-names></name><name><surname>Santos</surname><given-names>M.S.</given-names></name><name><surname>Seica</surname><given-names>R.</given-names></name></person-group><article-title>Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters</article-title><source>Synapse (New York, NY)</source><volume>65</volume><issue>6</issue><year>2011</year><fpage>457</fpage><lpage>466</lpage></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Santos</surname><given-names>R.X.</given-names></name><name><surname>Correia</surname><given-names>S.C.</given-names></name><name><surname>Carvalho</surname><given-names>C.</given-names></name><name><surname>Santos</surname><given-names>M.S.</given-names></name><name><surname>Baldeiras</surname><given-names>I.</given-names></name></person-group><article-title>Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance</article-title><source>Neurobiol. Dis.</source><volume>49</volume><year>2013</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">22940631</pub-id></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Correia</surname><given-names>S.C.</given-names></name><name><surname>Santos</surname><given-names>R.X.</given-names></name><name><surname>Carvalho</surname><given-names>C.</given-names></name><name><surname>Candeias</surname><given-names>E.</given-names></name><name><surname>Duarte</surname><given-names>A.I.</given-names></name></person-group><article-title>Hyperglycemia, hypoglycemia and dementia: role of mitochondria and uncoupling proteins</article-title><source>Curr. Mol. Med.</source><volume>13</volume><issue>4</issue><year>2013</year><fpage>586</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">22934852</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Correia</surname><given-names>S.</given-names></name><name><surname>Carvalho</surname><given-names>C.</given-names></name><name><surname>Candeias</surname><given-names>E.</given-names></name><name><surname>Placido</surname><given-names>A.I.</given-names></name><name><surname>Duarte</surname><given-names>A.I.</given-names></name></person-group><article-title>Perspectives on mitochondrial uncoupling proteins-mediated neuroprotection</article-title><source>J. Bioenerg. Biomembr.</source><volume>47</volume><issue>1&#x02013;2</issue><year>2015</year><fpage>119</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">25217852</pub-id></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>S.</given-names></name><name><surname>Seica</surname><given-names>R.M.</given-names></name><name><surname>Moreira</surname><given-names>P.I.</given-names></name></person-group><article-title>Uncoupling protein 2 inhibition exacerbates glucose fluctuation-mediated neuronal effects</article-title><source>Neurotox. Res.</source><volume>33</volume><issue>2</issue><year>2018</year><fpage>388</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">28875237</pub-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Carrero</surname><given-names>I.</given-names></name><name><surname>Gonzalo</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>B.</given-names></name><name><surname>Sanz-Anquela</surname><given-names>J.</given-names></name><name><surname>Arevalo-Serrano</surname><given-names>J.</given-names></name><name><surname>Gonzalo-Ruiz</surname><given-names>A.</given-names></name></person-group><article-title>Oligomers of beta-amyloid protein (A&#x003b2;1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain</article-title><source>Exp. Neurol.</source><volume>236</volume><issue>2</issue><year>2012</year><fpage>215</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">22617488</pub-id></element-citation></ref><ref id="b0195"><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>C.</given-names></name><name><surname>Correia</surname><given-names>S.C.</given-names></name><name><surname>Santos</surname><given-names>M.S.</given-names></name><name><surname>Baldeiras</surname><given-names>I.</given-names></name><name><surname>Oliveira</surname><given-names>C.R.</given-names></name><name><surname>Seica</surname><given-names>R.</given-names></name></person-group><article-title>Vascular, oxidative, and synaptosomal abnormalities during aging and the progression of type 2 diabetes</article-title><source>Curr. Neurovasc. Res.</source><volume>11</volume><issue>4</issue><year>2014</year><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">25182811</pub-id></element-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.-J.</given-names></name><name><surname>Do Koo</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Ahn</surname><given-names>B.Y.</given-names></name></person-group><article-title>A mitochondrial proteome profile indicative of type 2 diabetes mellitus in skeletal muscles</article-title><source>Exp. Mol. Med.</source><volume>50</volume><issue>9</issue><year>2018</year><fpage>129</fpage><pub-id pub-id-type="pmid">30266947</pub-id></element-citation></ref><ref id="b0205"><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>R.C.C.</given-names></name><name><surname>Suen</surname><given-names>K.C.</given-names></name><name><surname>Ma</surname><given-names>C.H.</given-names></name><name><surname>Elyaman</surname><given-names>W.</given-names></name><name><surname>Ng</surname><given-names>H.K.</given-names></name><name><surname>Hugon</surname><given-names>J.</given-names></name></person-group><article-title>Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2&#x003b1; in neuronal degeneration</article-title><source>J. Neurochem.</source><volume>83</volume><issue>5</issue><year>2002</year><fpage>1215</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">12437593</pub-id></element-citation></ref><ref id="b0210"><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Tseng</surname><given-names>Y.</given-names></name><name><surname>White</surname><given-names>M.F.</given-names></name></person-group><article-title>Insulin signaling meets mitochondria in metabolism</article-title><source>Trends Endocrinol. Metab.</source><volume>21</volume><issue>10</issue><year>2010</year><fpage>589</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">20638297</pub-id></element-citation></ref><ref id="b0215"><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>S.-L.</given-names></name><name><surname>Chen</surname><given-names>C.-M.</given-names></name><name><surname>Cline</surname><given-names>H.T.</given-names></name></person-group><article-title>Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo</article-title><source>Neuron</source><volume>58</volume><issue>5</issue><year>2008</year><fpage>708</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">18549783</pub-id></element-citation></ref><ref id="b0220"><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Choudhary</surname><given-names>S.</given-names></name><name><surname>Sinha</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Sathyanarayana</surname><given-names>P.</given-names></name><name><surname>Shahani</surname><given-names>S.</given-names></name></person-group><article-title>NF-&#x003ba;B-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin</article-title><source>Endocrinology</source><volume>152</volume><issue>10</issue><year>2011</year><fpage>3622</fpage><lpage>3627</lpage><pub-id pub-id-type="pmid">21846802</pub-id></element-citation></ref><ref id="b0225"><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>I.A.</given-names></name><name><surname>Vissel</surname><given-names>B.</given-names></name></person-group><article-title>Inflammation-sleep interface in brain disease: TNF, insulin, orexin</article-title><source>J. Neuroinflam.</source><volume>11</volume><issue>1</issue><year>2014</year><fpage>51</fpage></element-citation></ref><ref id="b0230"><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Claxton</surname><given-names>A.</given-names></name><name><surname>Baker</surname><given-names>L.D.</given-names></name><name><surname>Hanson</surname><given-names>A.</given-names></name><name><surname>Trittschuh</surname><given-names>E.H.</given-names></name><name><surname>Cholerton</surname><given-names>B.</given-names></name><name><surname>Morgan</surname><given-names>A.</given-names></name></person-group><article-title>Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia</article-title><source>J. Alzheimers Dis.</source><volume>44</volume><issue>3</issue><year>2015</year><fpage>897</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">25374101</pub-id></element-citation></ref><ref id="b0235"><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Collino</surname><given-names>M.</given-names></name><name><surname>Patel</surname><given-names>N.S.</given-names></name><name><surname>Thiemermann</surname><given-names>C.</given-names></name></person-group><article-title>PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury</article-title><source>Therap. Adv. Cardiovasc. Dis.</source><volume>2</volume><issue>3</issue><year>2008</year><fpage>179</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">19124421</pub-id></element-citation></ref><ref id="b0240"><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name><surname>Combs</surname><given-names>C.K.</given-names></name><name><surname>Johnson</surname><given-names>D.E.</given-names></name><name><surname>Karlo</surname><given-names>J.C.</given-names></name><name><surname>Cannady</surname><given-names>S.B.</given-names></name><name><surname>Landreth</surname><given-names>G.E.</given-names></name></person-group><article-title>Inflammatory mechanisms in Alzheimer's disease: inhibition of &#x003b2;-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR&#x003b3; agonists</article-title><source>J. Neurosci.</source><volume>20</volume><issue>2</issue><year>2000</year><fpage>558</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">10632585</pub-id></element-citation></ref><ref id="b0245"><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name><surname>Corcoran</surname><given-names>N.M.</given-names></name><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Hutter-Paier</surname><given-names>B.</given-names></name><name><surname>Windisch</surname><given-names>M.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name><name><surname>Nheu</surname><given-names>L.</given-names></name></person-group><article-title>Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer&#x02019;s disease model</article-title><source>J. Clin. Neurosci.</source><volume>17</volume><issue>8</issue><year>2010</year><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">20537899</pub-id></element-citation></ref><ref id="b0250"><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name><surname>Corona</surname><given-names>A.W.</given-names></name><name><surname>Fenn</surname><given-names>A.M.</given-names></name><name><surname>Godbout</surname><given-names>J.P.</given-names></name></person-group><article-title>Cognitive and behavioral consequences of impaired immunoregulation in aging</article-title><source>J. Neuroimmune Pharmacol.</source><volume>7</volume><issue>1</issue><year>2012</year><fpage>7</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">21932047</pub-id></element-citation></ref><ref id="b0255"><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>S.C.</given-names></name><name><surname>Santos</surname><given-names>R.X.</given-names></name><name><surname>Santos</surname><given-names>M.S.</given-names></name><name><surname>Casadesus</surname><given-names>G.</given-names></name><name><surname>Lamanna</surname><given-names>J.C.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name></person-group><article-title>Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease</article-title><source>Curr. Alzheimer Res.</source><volume>10</volume><issue>4</issue><year>2013</year><fpage>406</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">23061885</pub-id></element-citation></ref><ref id="b0260"><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name><surname>Craft</surname><given-names>S.</given-names></name><name><surname>Asthana</surname><given-names>S.</given-names></name><name><surname>Schellenberg</surname><given-names>G.</given-names></name><name><surname>Baker</surname><given-names>L.</given-names></name><name><surname>Cherrier</surname><given-names>M.</given-names></name><name><surname>Boyt</surname><given-names>A.A.</given-names></name></person-group><article-title>Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>903</volume><issue>1</issue><year>2000</year><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">10818510</pub-id></element-citation></ref><ref id="b0265"><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>G.</given-names></name><name><surname>Ritter</surname><given-names>A.</given-names></name><name><surname>Zhong</surname><given-names>K.</given-names></name></person-group><article-title>Alzheimer's disease drug development pipeline: 2018</article-title><source>Alzheimer's Dementia: Transl. Res. Clin. Intervent.</source><volume>4</volume><year>2018</year><fpage>195</fpage><lpage>214</lpage></element-citation></ref><ref id="b0270"><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name><surname>Damcott</surname><given-names>C.M.</given-names></name><name><surname>Pollin</surname><given-names>T.I.</given-names></name><name><surname>Reinhart</surname><given-names>L.J.</given-names></name><name><surname>Ott</surname><given-names>S.H.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Silver</surname><given-names>K.D.</given-names></name></person-group><article-title>Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance</article-title><source>Diabetes</source><volume>55</volume><issue>9</issue><year>2006</year><fpage>2654</fpage><lpage>2659</lpage><pub-id pub-id-type="pmid">16936218</pub-id></element-citation></ref><ref id="b0275"><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>M.</given-names></name><name><surname>Reiser</surname><given-names>P.</given-names></name><name><surname>Gumula</surname><given-names>N.</given-names></name><name><surname>Hertzog</surname><given-names>B.</given-names></name><name><surname>Andrade-Gordon</surname><given-names>P.</given-names></name></person-group><article-title>Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer's disease</article-title><source>Biotech. Histochem.</source><volume>76</volume><issue>2</issue><year>2001</year><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">11440311</pub-id></element-citation></ref><ref id="b0280"><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>F.G.</given-names></name><name><surname>Velasco</surname><given-names>P.T.</given-names></name><name><surname>Lambert</surname><given-names>M.P.</given-names></name><name><surname>Viola</surname><given-names>K.</given-names></name><name><surname>Fernandez</surname><given-names>S.J.</given-names></name><name><surname>Ferreira</surname><given-names>S.T.</given-names></name></person-group><article-title>A&#x003b2; oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine</article-title><source>J. Biol. Chem.</source><volume>282</volume><issue>15</issue><year>2007</year><fpage>11590</fpage><lpage>11601</lpage><pub-id pub-id-type="pmid">17308309</pub-id></element-citation></ref><ref id="b0285"><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>Fernanda G.</given-names></name><name><surname>Vieira</surname><given-names>Marcelo N.N.</given-names></name><name><surname>Bomfim</surname><given-names>Theresa R.</given-names></name><name><surname>Decker</surname><given-names>Helena</given-names></name><name><surname>Velasco</surname><given-names>Pauline T.</given-names></name><name><surname>Lambert</surname><given-names>Mary P.</given-names></name><name><surname>Viola</surname><given-names>Kirsten L.</given-names></name><name><surname>Zhao</surname><given-names>Wei-Qin</given-names></name><name><surname>Ferreira</surname><given-names>Sergio T.</given-names></name><name><surname>Klein</surname><given-names>William L.</given-names></name></person-group><article-title>Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of A&#x003b2; oligomers</article-title><source>PNAS</source><volume>106</volume><issue>6</issue><year>2009</year><fpage>1971</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">19188609</pub-id></element-citation></ref><ref id="b0290"><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>F.G.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Lambert</surname><given-names>M.P.</given-names></name><name><surname>Fernandez</surname><given-names>S.J.</given-names></name><name><surname>Velasco</surname><given-names>P.T.</given-names></name><name><surname>Lacor</surname><given-names>P.N.</given-names></name></person-group><article-title>Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A&#x003b2; oligomers</article-title><source>Neurobiol. Aging</source><volume>29</volume><issue>9</issue><year>2008</year><fpage>1334</fpage><lpage>1347</lpage><pub-id pub-id-type="pmid">17403556</pub-id></element-citation></ref><ref id="b0295"><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name><surname>de la Monte</surname><given-names>S.M.</given-names></name><name><surname>Wands</surname><given-names>J.R.</given-names></name></person-group><article-title>Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease</article-title><source>J. Alzheimers Dis.</source><volume>9</volume><issue>2</issue><year>2006</year><fpage>167</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">16873964</pub-id></element-citation></ref><ref id="b0300"><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name><surname>de la Monte</surname><given-names>S.M.</given-names></name><name><surname>Wands</surname><given-names>J.R.</given-names></name></person-group><article-title>Alzheimer's disease is type 3 diabetes-evidence reviewed</article-title><source>J. Diabetes Sci. Technol.</source><volume>2</volume><issue>6</issue><year>2008</year><fpage>1101</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">19885299</pub-id></element-citation></ref><ref id="b0305"><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name><surname>De Souza</surname><given-names>C.T.</given-names></name><name><surname>Araujo</surname><given-names>E.P.</given-names></name><name><surname>Bordin</surname><given-names>S.</given-names></name><name><surname>Ashimine</surname><given-names>R.</given-names></name><name><surname>Zollner</surname><given-names>R.L.</given-names></name><name><surname>Boschero</surname><given-names>A.C.</given-names></name></person-group><article-title>Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus</article-title><source>Endocrinology</source><volume>146</volume><issue>10</issue><year>2005</year><fpage>4192</fpage><lpage>4199</lpage><pub-id pub-id-type="pmid">16002529</pub-id></element-citation></ref><ref id="b0310"><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>H.</given-names></name><name><surname>Lo</surname><given-names>K.Y.</given-names></name><name><surname>Unger</surname><given-names>S.M.</given-names></name><name><surname>Ferreira</surname><given-names>S.T.</given-names></name><name><surname>Silverman</surname><given-names>M.A.</given-names></name></person-group><article-title>Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons</article-title><source>J. Neurosci.: Off. J. Soc. Neurosci.</source><volume>30</volume><issue>27</issue><year>2010</year><fpage>9166</fpage><lpage>9171</lpage></element-citation></ref><ref id="b0315"><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name><surname>Eckman</surname><given-names>E.</given-names></name><name><surname>Eckman</surname><given-names>C.</given-names></name></person-group><article-title>A&#x003b2;-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention</article-title><source>Biochem. Soc. Trans.</source><volume>33</volume><issue>5</issue><year>2005</year><fpage>1101</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">16246055</pub-id></element-citation></ref><ref id="b0320"><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name><surname>Farris</surname><given-names>W.</given-names></name><name><surname>Mansourian</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Lindsley</surname><given-names>L.</given-names></name><name><surname>Eckman</surname><given-names>E.A.</given-names></name><name><surname>Frosch</surname><given-names>M.P.</given-names></name></person-group><article-title>Insulin-degrading enzyme regulates the levels of insulin, amyloid &#x003b2;-protein, and the &#x003b2;-amyloid precursor protein intracellular domain in vivo</article-title><source>Proc. Natl. Acad. Sci.</source><volume>100</volume><issue>7</issue><year>2003</year><fpage>4162</fpage><lpage>4167</lpage><pub-id pub-id-type="pmid">12634421</pub-id></element-citation></ref><ref id="b0325"><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name><surname>Fernandez-Gamba</surname><given-names>A.</given-names></name><name><surname>Leal</surname><given-names>M.</given-names></name><name><surname>Morelli</surname><given-names>L.</given-names></name><name><surname>Castano</surname><given-names>E.</given-names></name></person-group><article-title>Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease</article-title><source>Curr. Pharm. Des.</source><volume>15</volume><issue>31</issue><year>2009</year><fpage>3644</fpage><lpage>3655</lpage><pub-id pub-id-type="pmid">19925417</pub-id></element-citation></ref><ref id="b0330"><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name><surname>Fontan-Lozano</surname><given-names>A.</given-names></name><name><surname>Lopez-Lluch</surname><given-names>G.</given-names></name><name><surname>Delgado-Garcia</surname><given-names>J.M.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Carrion</surname><given-names>A.M.</given-names></name></person-group><article-title>Molecular bases of caloric restriction regulation of neuronal synaptic plasticity</article-title><source>Mol. Neurobiol.</source><volume>38</volume><issue>2</issue><year>2008</year><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">18759009</pub-id></element-citation></ref><ref id="b0335"><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name><surname>Frayling</surname><given-names>T.M.</given-names></name><name><surname>Timpson</surname><given-names>N.J.</given-names></name><name><surname>Weedon</surname><given-names>M.N.</given-names></name><name><surname>Zeggini</surname><given-names>E.</given-names></name><name><surname>Freathy</surname><given-names>R.M.</given-names></name><name><surname>Lindgren</surname><given-names>C.M.</given-names></name></person-group><article-title>A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity</article-title><source>Science (New York, NY)</source><year>2007</year></element-citation></ref><ref id="b0340"><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name><surname>Frieden</surname><given-names>C.</given-names></name><name><surname>Garai</surname><given-names>K.</given-names></name></person-group><article-title>Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer&#x02019;s disease</article-title><source>Proc. Natl. Acad. Sci.</source><volume>109</volume><issue>23</issue><year>2012</year><fpage>8913</fpage><lpage>8918</lpage><pub-id pub-id-type="pmid">22615372</pub-id></element-citation></ref><ref id="b0345"><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name><surname>Gariballa</surname><given-names>S.</given-names></name><name><surname>Kosanovic</surname><given-names>M.</given-names></name><name><surname>Yasin</surname><given-names>J.</given-names></name><name><surname>Essa</surname><given-names>A.E.</given-names></name></person-group><article-title>Oxidative damage and inflammation in obese diabetic emirati subjects</article-title><source>Nutrients.</source><volume>6</volume><issue>11</issue><year>2014</year><fpage>4872</fpage><pub-id pub-id-type="pmid">25375631</pub-id></element-citation></ref><ref id="b0350"><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name><surname>Gejl</surname><given-names>M.</given-names></name><name><surname>Gjedde</surname><given-names>A.</given-names></name><name><surname>Egefjord</surname><given-names>L.</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>A.</given-names></name><name><surname>Hansen</surname><given-names>S.B.</given-names></name><name><surname>Vang</surname><given-names>K.</given-names></name></person-group><article-title>In Alzheimer&#x02019;s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial</article-title><source>Front. Aging Neurosci.</source><volume>8</volume><year>2016</year><fpage>108</fpage><pub-id pub-id-type="pmid">27252647</pub-id></element-citation></ref><ref id="b0355"><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name><surname>Ghasemi</surname><given-names>R.</given-names></name><name><surname>Haeri</surname><given-names>A.</given-names></name><name><surname>Dargahi</surname><given-names>L.</given-names></name><name><surname>Mohamed</surname><given-names>Z.</given-names></name><name><surname>Ahmadiani</surname><given-names>A.</given-names></name></person-group><article-title>Insulin in the brain: sources, localization and functions</article-title><source>Mol. Neurobiol.</source><volume>47</volume><issue>1</issue><year>2013</year><fpage>145</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">22956272</pub-id></element-citation></ref><ref id="b0360"><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name><surname>Gouw</surname><given-names>A.A.</given-names></name><name><surname>van der Flier</surname><given-names>W.M.</given-names></name><name><surname>Fazekas</surname><given-names>F.</given-names></name><name><surname>van Straaten</surname><given-names>E.C.</given-names></name><name><surname>Pantoni</surname><given-names>L.</given-names></name><name><surname>Poggesi</surname><given-names>A.</given-names></name></person-group><article-title>Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study</article-title><source>Stroke</source><volume>39</volume><issue>5</issue><year>2008</year><fpage>1414</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">18323505</pub-id></element-citation></ref><ref id="b0365"><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name><surname>Gratuze</surname><given-names>M.</given-names></name><name><surname>Julien</surname><given-names>J.</given-names></name><name><surname>Petry</surname><given-names>F.R.</given-names></name><name><surname>Morin</surname><given-names>F.</given-names></name><name><surname>Planel</surname><given-names>E.</given-names></name></person-group><article-title>Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer&#x02019;s disease-like tau pathology</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>46359</fpage><pub-id pub-id-type="pmid">28402338</pub-id></element-citation></ref><ref id="b0370"><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name><surname>Gratuze</surname><given-names>M.</given-names></name><name><surname>Joly-Amado</surname><given-names>A.</given-names></name><name><surname>Vieau</surname><given-names>D.</given-names></name><name><surname>Bu&#x000e9;e</surname><given-names>L.</given-names></name><name><surname>Blum</surname><given-names>D.</given-names></name></person-group><article-title>Mutual relationship between tau and central insulin signalling: consequences for AD and Tauopathies?</article-title><source>Neuroendocrinology</source><volume>107</volume><issue>2</issue><year>2018</year><fpage>181</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">29439247</pub-id></element-citation></ref><ref id="b0375"><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name><surname>Grbovic</surname><given-names>O.M.</given-names></name><name><surname>Mathews</surname><given-names>P.M.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Schmidt</surname><given-names>S.D.</given-names></name><name><surname>Dinakar</surname><given-names>R.</given-names></name><name><surname>Summers-Terio</surname><given-names>N.B.</given-names></name></person-group><article-title>Rab5-stimulated up-regulation of the endocytic pathway increases intracellular levels of betaCTFs and Abeta production</article-title><source>J. Biol. Chem.</source><year>2003</year></element-citation></ref><ref id="b0380"><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Fratiglioni</surname><given-names>L.</given-names></name><name><surname>Viitanen</surname><given-names>M.</given-names></name><name><surname>Lannfelt</surname><given-names>L.</given-names></name><name><surname>Basun</surname><given-names>H.</given-names></name><name><surname>Fastbom</surname><given-names>J.</given-names></name></person-group><article-title>Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication?</article-title><source>Am. J. Epidemiol.</source><volume>153</volume><issue>3</issue><year>2001</year><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">11157409</pub-id></element-citation></ref><ref id="b0385"><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name><surname>Habibzadeh</surname><given-names>F.</given-names></name></person-group><article-title>Hypertension in the Middle East</article-title><source>Acta Biomed.</source><volume>82</volume><year>2011</year><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">22783719</pub-id></element-citation></ref><ref id="b0390"><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name><surname>Hajat</surname><given-names>C.</given-names></name><name><surname>Harrison</surname><given-names>O.</given-names></name><name><surname>Shather</surname><given-names>Z.</given-names></name></person-group><article-title>A profile and approach to chronic disease in Abu Dhabi</article-title><source>Globalization Health</source><volume>8</volume><issue>1</issue><year>2012</year><fpage>18</fpage><pub-id pub-id-type="pmid">22738714</pub-id></element-citation></ref><ref id="b0395"><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name><surname>Hajjar</surname><given-names>R.R.</given-names></name><name><surname>Atli</surname><given-names>T.</given-names></name><name><surname>Al-Mandhari</surname><given-names>Z.</given-names></name><name><surname>Oudrhiri</surname><given-names>M.</given-names></name><name><surname>Balducci</surname><given-names>L.</given-names></name><name><surname>Silbermann</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence of aging population in the Middle East and its implications on cancer incidence and care</article-title><source>Ann. Oncol.</source><volume>24</volume><issue>suppl 7</issue><year>2013</year><fpage>vii11</fpage><lpage>vii24</lpage><pub-id pub-id-type="pmid">24001758</pub-id></element-citation></ref><ref id="b0400"><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name><surname>Hak</surname><given-names>A.E.</given-names></name><name><surname>Pols</surname><given-names>H.A.</given-names></name><name><surname>Stehouwer</surname><given-names>C.D.</given-names></name><name><surname>Meijer</surname><given-names>J.</given-names></name><name><surname>Kiliaan</surname><given-names>A.J.</given-names></name><name><surname>Hofman</surname><given-names>A.</given-names></name></person-group><article-title>Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study</article-title><source>J. Clin. Endocrinol. Metabol.</source><volume>86</volume><issue>9</issue><year>2001</year><fpage>4398</fpage><lpage>4405</lpage></element-citation></ref><ref id="b0405"><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>Y.</given-names></name><name><surname>Yuk</surname><given-names>F.</given-names></name><name><surname>Puri</surname><given-names>R.</given-names></name><name><surname>Janssen</surname><given-names>W.G.</given-names></name><name><surname>Rapp</surname><given-names>P.R.</given-names></name><name><surname>Morrison</surname><given-names>J.H.</given-names></name></person-group><article-title>Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment</article-title><source>PNAS</source><volume>111</volume><issue>1</issue><year>2014</year><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">24297907</pub-id></element-citation></ref><ref id="b0410"><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics</article-title><source>Science (New York, NY)</source><volume>297</volume><issue>5580</issue><year>2002</year><fpage>353</fpage><lpage>356</lpage></element-citation></ref><ref id="b0415"><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name><surname>Hatters</surname><given-names>D.M.</given-names></name><name><surname>Zhong</surname><given-names>N.</given-names></name><name><surname>Rutenber</surname><given-names>E.</given-names></name><name><surname>Weisgraber</surname><given-names>K.H.</given-names></name></person-group><article-title>Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils</article-title><source>J. Mol. Biol.</source><volume>361</volume><issue>5</issue><year>2006</year><fpage>932</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">16890957</pub-id></element-citation></ref><ref id="b0420"><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H.</given-names></name><name><surname>Campenot</surname><given-names>R.B.</given-names></name><name><surname>Vance</surname><given-names>D.E.</given-names></name><name><surname>Vance</surname><given-names>J.E.</given-names></name></person-group><article-title>Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures</article-title><source>J. Biol. Chem.</source><volume>279</volume><issue>14</issue><year>2004</year><fpage>14009</fpage><lpage>14015</lpage><pub-id pub-id-type="pmid">14709547</pub-id></element-citation></ref><ref id="b0425"><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name><surname>Hebbar</surname><given-names>P.</given-names></name><name><surname>Abubaker</surname><given-names>J.A.</given-names></name><name><surname>Abu-Farha</surname><given-names>M.</given-names></name><name><surname>Tuomilehto</surname><given-names>J.</given-names></name><name><surname>Al-Mulla</surname><given-names>F.</given-names></name><name><surname>Thanaraj</surname><given-names>T.A.</given-names></name></person-group><article-title>A perception on genome-wide genetic analysis of metabolic traits in Arab populations</article-title><source>Front. Endocrinol.</source><volume>10</volume><year>2019</year><fpage>8</fpage></element-citation></ref><ref id="b0430"><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name><surname>Herder</surname><given-names>C.</given-names></name><name><surname>Rathmann</surname><given-names>W.</given-names></name><name><surname>Strassburger</surname><given-names>K.</given-names></name><name><surname>Finner</surname><given-names>H.</given-names></name><name><surname>Grallert</surname><given-names>H.</given-names></name><name><surname>Huth</surname><given-names>C.</given-names></name></person-group><article-title>Variants of the PPARG, IGF2BP2, CDKAL1, HHEX, and TCF7L2 genes confer risk of type 2 diabetes independently of BMI in the German KORA studies</article-title><source>Horm. Metab. Res.</source><volume>40</volume><issue>10</issue><year>2008</year><fpage>722</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">18597214</pub-id></element-citation></ref><ref id="b0435"><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name><surname>Hirosumi</surname><given-names>J.</given-names></name><name><surname>Tuncman</surname><given-names>G.</given-names></name><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Gorgun</surname><given-names>C.Z.</given-names></name><name><surname>Uysal</surname><given-names>K.T.</given-names></name><name><surname>Maeda</surname><given-names>K.</given-names></name></person-group><article-title>A central role for JNK in obesity and insulin resistance</article-title><source>Nature</source><volume>420</volume><issue>6913</issue><year>2002</year><fpage>333</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">12447443</pub-id></element-citation></ref><ref id="b0440"><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name><surname>Hirsch-Reinshagen</surname><given-names>V.</given-names></name><name><surname>Maia</surname><given-names>L.F.</given-names></name><name><surname>Burgess</surname><given-names>B.L.</given-names></name><name><surname>Blain</surname><given-names>J.-F.</given-names></name><name><surname>Naus</surname><given-names>K.E.</given-names></name><name><surname>McIsaac</surname><given-names>S.A.</given-names></name></person-group><article-title>The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease</article-title><source>J. Biol. Chem.</source><volume>280</volume><issue>52</issue><year>2005</year><fpage>43243</fpage><lpage>43256</lpage><pub-id pub-id-type="pmid">16207707</pub-id></element-citation></ref><ref id="b0445"><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name><surname>Hochgr&#x000e4;fe</surname><given-names>K.</given-names></name><name><surname>Sydow</surname><given-names>A.</given-names></name><name><surname>Mandelkow</surname><given-names>E.M.</given-names></name></person-group><article-title>Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology</article-title><source>FEBS J.</source><volume>280</volume><issue>18</issue><year>2013</year><fpage>4371</fpage><lpage>4381</lpage><pub-id pub-id-type="pmid">23517246</pub-id></element-citation></ref><ref id="b0450"><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name><surname>Honig</surname><given-names>L.S.</given-names></name><name><surname>Vellas</surname><given-names>B.</given-names></name><name><surname>Woodward</surname><given-names>M.</given-names></name><name><surname>Boada</surname><given-names>M.</given-names></name><name><surname>Bullock</surname><given-names>R.</given-names></name><name><surname>Borrie</surname><given-names>M.</given-names></name></person-group><article-title>Trial of solanezumab for mild dementia due to Alzheimer&#x02019;s disease</article-title><source>N. Engl. J. Med.</source><volume>378</volume><issue>4</issue><year>2018</year><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">29365294</pub-id></element-citation></ref><ref id="b0455"><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name><surname>Hoozemans</surname><given-names>J.J.</given-names></name><name><surname>van Haastert</surname><given-names>E.S.</given-names></name><name><surname>Nijholt</surname><given-names>D.A.</given-names></name><name><surname>Rozemuller</surname><given-names>A.J.</given-names></name><name><surname>Eikelenboom</surname><given-names>P.</given-names></name><name><surname>Scheper</surname><given-names>W.</given-names></name></person-group><article-title>The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus</article-title><source>Am. J. Pathol.</source><volume>174</volume><issue>4</issue><year>2009</year><fpage>1241</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">19264902</pub-id></element-citation></ref><ref id="b0460"><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.Q.</given-names></name><name><surname>Wyss-Coray</surname><given-names>T.</given-names></name><name><surname>Brecht</surname><given-names>W.J.</given-names></name><name><surname>Sanan</surname><given-names>D.A.</given-names></name><name><surname>Mahley</surname><given-names>R.W.</given-names></name></person-group><article-title>Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons</article-title><source>Proc. Natl. Acad. Sci.</source><volume>98</volume><issue>15</issue><year>2001</year><fpage>8838</fpage><lpage>8843</lpage><pub-id pub-id-type="pmid">11447277</pub-id></element-citation></ref><ref id="b0465"><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name><surname>Ikawa</surname><given-names>M.</given-names></name><name><surname>Arakawa</surname><given-names>K.</given-names></name><name><surname>Hamano</surname><given-names>T.</given-names></name><name><surname>Nagata</surname><given-names>M.</given-names></name><name><surname>Nakamoto</surname><given-names>Y.</given-names></name><name><surname>Kuriyama</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of systemic redox states in patients carrying the MELAS A3243G mutation in mitochondrial DNA</article-title><source>Eur. Neurol.</source><volume>67</volume><issue>4</issue><year>2012</year><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">22517274</pub-id></element-citation></ref><ref id="b0470"><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name><surname>Infante-Garcia</surname><given-names>C.</given-names></name><name><surname>Ramos-Rodriguez</surname><given-names>J.J.</given-names></name><name><surname>Galindo-Gonzalez</surname><given-names>L.</given-names></name><name><surname>Garcia-Alloza</surname><given-names>M.</given-names></name></person-group><article-title>Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer&#x02019;s disease and type 2 diabetes</article-title><source>Psychoneuroendocrinology</source><volume>65</volume><year>2016</year><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">26708068</pub-id></element-citation></ref><ref id="b0475"><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name><surname>Inzelberg</surname><given-names>R.</given-names></name><name><surname>Massarwa</surname><given-names>M.</given-names></name><name><surname>Schechtman</surname><given-names>E.</given-names></name><name><surname>Strugatsky</surname><given-names>R.</given-names></name><name><surname>Farrer</surname><given-names>L.A.</given-names></name><name><surname>Friedland</surname><given-names>R.P.</given-names></name></person-group><article-title>Estimating the risk for conversion from mild cognitive impairment to Alzheimer's disease in an elderly Arab community</article-title><source>J. Alzheimer's Dis.: JAD</source><volume>45</volume><issue>3</issue><year>2015</year><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">25624416</pub-id></element-citation></ref><ref id="b0480"><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>K.</given-names></name><name><surname>Alonso</surname><given-names>A.d.C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chohan</surname><given-names>M.O.</given-names></name><name><surname>El-Akkad</surname><given-names>E.</given-names></name><name><surname>Gong</surname><given-names>C.-X.</given-names></name></person-group><article-title>Tau pathology in Alzheimer disease and other tauopathies</article-title><source>Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.</source><volume>1739</volume><issue>2&#x02013;3</issue><year>2005</year><fpage>198</fpage><lpage>210</lpage></element-citation></ref><ref id="b0485"><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name><surname>Irie</surname><given-names>F.</given-names></name><name><surname>Fitzpatrick</surname><given-names>A.L.</given-names></name><name><surname>Lopez</surname><given-names>O.L.</given-names></name><name><surname>Kuller</surname><given-names>L.H.</given-names></name><name><surname>Peila</surname><given-names>R.</given-names></name><name><surname>Newman</surname><given-names>A.B.</given-names></name></person-group><article-title>Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE &#x003b5;4: the Cardiovascular Health Study Cognition Study</article-title><source>Arch. Neurol.</source><volume>65</volume><issue>1</issue><year>2008</year><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">18195144</pub-id></element-citation></ref><ref id="b0490"><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name><surname>Jaeschke</surname><given-names>A.</given-names></name><name><surname>Czech</surname><given-names>M.P.</given-names></name><name><surname>Davis</surname><given-names>R.J.</given-names></name></person-group><article-title>An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue</article-title><source>Genes Dev.</source><volume>18</volume><issue>16</issue><year>2004</year><fpage>1976</fpage><lpage>1980</lpage><pub-id pub-id-type="pmid">15314024</pub-id></element-citation></ref><ref id="b0495"><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name><surname>Janson</surname><given-names>J.</given-names></name><name><surname>Laedtke</surname><given-names>T.</given-names></name><name><surname>Parisi</surname><given-names>J.E.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>P.</given-names></name><name><surname>Petersen</surname><given-names>R.C.</given-names></name><name><surname>Butler</surname><given-names>P.C.</given-names></name></person-group><article-title>Increased risk of type 2 diabetes in Alzheimer disease</article-title><source>Diabetes</source><volume>53</volume><issue>2</issue><year>2004</year><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">14747300</pub-id></element-citation></ref><ref id="b0500"><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>L.A.</given-names></name><name><surname>Torres</surname><given-names>E.R.</given-names></name><name><surname>Impey</surname><given-names>S.</given-names></name><name><surname>Stevens</surname><given-names>J.F.</given-names></name><name><surname>Raber</surname><given-names>J.</given-names></name></person-group><article-title>Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>43701</fpage><pub-id pub-id-type="pmid">28272510</pub-id></element-citation></ref><ref id="b0505"><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name><surname>Kaido</surname><given-names>M.</given-names></name><name><surname>Fujimura</surname><given-names>H.</given-names></name><name><surname>Soga</surname><given-names>F.</given-names></name><name><surname>Toyooka</surname><given-names>K.</given-names></name><name><surname>Yoshikawa</surname><given-names>H.</given-names></name><name><surname>Nishimura</surname><given-names>T.</given-names></name></person-group><article-title>Alzheimer-type pathology in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)</article-title><source>Acta Neuropathol.</source><volume>92</volume><issue>3</issue><year>1996</year><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">8870835</pub-id></element-citation></ref><ref id="b0510"><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>D.</given-names></name><name><surname>Trikha</surname><given-names>D.</given-names></name><name><surname>Vijayvergiya</surname><given-names>R.</given-names></name><name><surname>Kaul</surname><given-names>D.</given-names></name><name><surname>Dhawan</surname><given-names>V.</given-names></name></person-group><article-title>Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: a system-based approach</article-title><source>Atherosclerosis</source><volume>237</volume><issue>2</issue><year>2014</year><fpage>623</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">25463097</pub-id></element-citation></ref><ref id="b0515"><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>Y.D.</given-names></name><name><surname>Delerue</surname><given-names>F.</given-names></name><name><surname>Gladbach</surname><given-names>A.</given-names></name><name><surname>G&#x000f6;tz</surname><given-names>J.</given-names></name><name><surname>Ittner</surname><given-names>L.M.</given-names></name></person-group><article-title>Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease</article-title><source>PLoS ONE</source><volume>4</volume><issue>11</issue><year>2009</year><object-id pub-id-type="publisher-id">e7917</object-id></element-citation></ref><ref id="b0520"><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name><surname>Khadir</surname><given-names>A.</given-names></name><name><surname>Kavalakatt</surname><given-names>S.</given-names></name><name><surname>Dehbi</surname><given-names>M.</given-names></name><name><surname>Alarouj</surname><given-names>M.</given-names></name><name><surname>Bennakhi</surname><given-names>A.</given-names></name><name><surname>Tiss</surname><given-names>A.</given-names></name></person-group><article-title>DUSP1 is a potential marker of chronic inflammation in arabs with cardiovascular diseases</article-title><source>Dis. Markers</source><volume>2018</volume><year>2018</year></element-citation></ref><ref id="b0525"><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>T.K.</given-names></name><name><surname>Alkon</surname><given-names>D.L.</given-names></name></person-group><article-title>Peripheral biomarkers of Alzheimer's disease</article-title><source>J. Alzheimer's Dis.: JAD</source><volume>44</volume><issue>3</issue><year>2015</year><fpage>729</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">25374110</pub-id></element-citation></ref><ref id="b0530"><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name><surname>Kickstein</surname><given-names>E.</given-names></name><name><surname>Krauss</surname><given-names>S.</given-names></name><name><surname>Thornhill</surname><given-names>P.</given-names></name><name><surname>Rutschow</surname><given-names>D.</given-names></name><name><surname>Zeller</surname><given-names>R.</given-names></name><name><surname>Sharkey</surname><given-names>J.</given-names></name></person-group><article-title>Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling</article-title><source>Proc. Natl. Acad. Sci.</source><volume>107</volume><issue>50</issue><year>2010</year><fpage>21830</fpage><lpage>21835</lpage><pub-id pub-id-type="pmid">21098287</pub-id></element-citation></ref><ref id="b0535"><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name><surname>Killick</surname><given-names>R.</given-names></name><name><surname>Scales</surname><given-names>G.</given-names></name><name><surname>Leroy</surname><given-names>K.</given-names></name><name><surname>Causevic</surname><given-names>M.</given-names></name><name><surname>Hooper</surname><given-names>C.</given-names></name><name><surname>Irvine</surname><given-names>E.E.</given-names></name></person-group><article-title>Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>386</volume><issue>1</issue><year>2009</year><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">19523444</pub-id></element-citation></ref><ref id="b0540"><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Kamei</surname><given-names>N.</given-names></name><name><surname>Shimada</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone</article-title><source>PLoS ONE</source><volume>8</volume><issue>12</issue><year>2013</year><object-id pub-id-type="publisher-id">e82847</object-id></element-citation></ref><ref id="b0545"><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>E.M.</given-names></name><name><surname>Martins</surname><given-names>I.V.</given-names></name><name><surname>Gumusgoz</surname><given-names>S.</given-names></name><name><surname>Allan</surname><given-names>S.M.</given-names></name><name><surname>Lawrence</surname><given-names>C.B.</given-names></name></person-group><article-title>High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology</article-title><source>Neurobiol. Aging</source><volume>35</volume><issue>8</issue><year>2014</year><fpage>1821</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">24630364</pub-id></element-citation></ref><ref id="b0550"><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>Y.H.</given-names></name><name><surname>von Arnim</surname><given-names>C.A.</given-names></name><name><surname>Hyman</surname><given-names>B.T.</given-names></name><name><surname>Tanzi</surname><given-names>R.E.</given-names></name><name><surname>Tesco</surname><given-names>G.</given-names></name></person-group><article-title>BACE is degraded via the lysosomal pathway</article-title><source>J. Biol. Chem.</source><volume>280</volume><issue>37</issue><year>2005</year><fpage>32499</fpage><lpage>32504</lpage><pub-id pub-id-type="pmid">16033761</pub-id></element-citation></ref><ref id="b0555"><element-citation publication-type="journal" id="h0555"><person-group person-group-type="author"><name><surname>Kolmychkova</surname><given-names>K.I.</given-names></name><name><surname>Zhelankin</surname><given-names>A.V.</given-names></name><name><surname>Karagodin</surname><given-names>V.P.</given-names></name><name><surname>Orekhov</surname><given-names>A.N.</given-names></name></person-group><article-title>Mitochondria and inflammation</article-title><source>Patologicheskaia fiziologiia i eksperimental'naia terapiia</source><volume>60</volume><issue>4</issue><year>2016</year><fpage>114</fpage><lpage>121</lpage></element-citation></ref><ref id="b0560"><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name><surname>Koschinsky</surname><given-names>T.</given-names></name><name><surname>He</surname><given-names>C.-J.</given-names></name><name><surname>Mitsuhashi</surname><given-names>T.</given-names></name><name><surname>Bucala</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Buenting</surname><given-names>C.</given-names></name></person-group><article-title>Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy</article-title><source>Proc. Natl. Acad. Sci.</source><volume>94</volume><issue>12</issue><year>1997</year><fpage>6474</fpage><lpage>6479</lpage><pub-id pub-id-type="pmid">9177242</pub-id></element-citation></ref><ref id="b0565"><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name><surname>Krasemann</surname><given-names>S.</given-names></name><name><surname>Madore</surname><given-names>C.</given-names></name><name><surname>Cialic</surname><given-names>R.</given-names></name><name><surname>Baufeld</surname><given-names>C.</given-names></name><name><surname>Calcagno</surname><given-names>N.</given-names></name><name><surname>El Fatimy</surname><given-names>R.</given-names></name></person-group><article-title>The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases</article-title><source>Immunity</source><volume>47</volume><issue>3</issue><year>2017</year><comment>566 81.e9</comment></element-citation></ref><ref id="b0570"><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name><surname>Kreisel</surname><given-names>S.H.</given-names></name><name><surname>Blahak</surname><given-names>C.</given-names></name><name><surname>B&#x000e4;zner</surname><given-names>H.</given-names></name><name><surname>Inzitari</surname><given-names>D.</given-names></name><name><surname>Pantoni</surname><given-names>L.</given-names></name><name><surname>Poggesi</surname><given-names>A.</given-names></name></person-group><article-title>Deterioration of gait and balance over time: the effects of age-related white matter change-the LADIS study</article-title><source>Cerebrovasc. Dis.</source><volume>35</volume><issue>6</issue><year>2013</year><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">23838682</pub-id></element-citation></ref><ref id="b0575"><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name><surname>Kubaszek</surname><given-names>A.</given-names></name><name><surname>Pihlajam&#x000e4;ki</surname><given-names>J.</given-names></name><name><surname>Komarovski</surname><given-names>V.</given-names></name><name><surname>Lindi</surname><given-names>V.</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>J.</given-names></name><name><surname>Eriksson</surname><given-names>J.</given-names></name></person-group><article-title>Promoter polymorphisms of the TNF-&#x003b1; (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study</article-title><source>Diabetes</source><volume>52</volume><issue>7</issue><year>2003</year><fpage>1872</fpage><lpage>1876</lpage><pub-id pub-id-type="pmid">12829659</pub-id></element-citation></ref><ref id="b0580"><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>J.C.</given-names></name><name><surname>Mann</surname><given-names>D.</given-names></name><name><surname>Harris</surname><given-names>J.</given-names></name><name><surname>Araria-Goumidi</surname><given-names>L.</given-names></name><name><surname>Chartier-Harlin</surname><given-names>M.C.</given-names></name><name><surname>Cottel</surname><given-names>D.</given-names></name></person-group><article-title>Association study of Notch 4 polymorphisms with Alzheimer's disease</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><volume>75</volume><issue>3</issue><year>2004</year><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">14966150</pub-id></element-citation></ref><ref id="b0585"><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name><surname>Lashley</surname><given-names>T.</given-names></name><name><surname>Holton</surname><given-names>J.L.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Kirkham</surname><given-names>K.</given-names></name><name><surname>O'Sullivan</surname><given-names>S.S.</given-names></name><name><surname>Hilbig</surname><given-names>A.</given-names></name></person-group><article-title>Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients</article-title><source>Acta Neuropathol.</source><volume>115</volume><issue>4</issue><year>2008</year><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">18185940</pub-id></element-citation></ref><ref id="b0590"><element-citation publication-type="journal" id="h0590"><person-group person-group-type="author"><name><surname>Lashley</surname><given-names>T.</given-names></name><name><surname>Schott</surname><given-names>J.M.</given-names></name><name><surname>Weston</surname><given-names>P.</given-names></name><name><surname>Murray</surname><given-names>C.E.</given-names></name><name><surname>Wellington</surname><given-names>H.</given-names></name><name><surname>Keshavan</surname><given-names>A.</given-names></name></person-group><article-title>Molecular biomarkers of Alzheimer's disease: progress and prospects</article-title><source>Dis. Models Mech.</source><volume>11</volume><issue>5</issue><year>2018</year></element-citation></ref><ref id="b0595"><element-citation publication-type="journal" id="h0595"><person-group person-group-type="author"><name><surname>Lawan</surname><given-names>A.</given-names></name><name><surname>Min</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Canfran-Duque</surname><given-names>A.</given-names></name><name><surname>Jurczak</surname><given-names>M.J.</given-names></name><name><surname>Camporez</surname><given-names>J.P.G.</given-names></name></person-group><article-title>Skeletal muscle-specific deletion of MKP-1 Reveals a p38 MAPK/JNK/Akt signaling node that regulates obesity-induced insulin resistance</article-title><source>Diabetes</source><volume>67</volume><issue>4</issue><year>2018</year><fpage>624</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">29317435</pub-id></element-citation></ref><ref id="b0600"><element-citation publication-type="journal" id="h0600"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.H.</given-names></name><name><surname>Giraud</surname><given-names>J.</given-names></name><name><surname>Davis</surname><given-names>R.J.</given-names></name><name><surname>White</surname><given-names>M.F.</given-names></name></person-group><article-title>c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade</article-title><source>J. Biol. Chem.</source><volume>278</volume><issue>5</issue><year>2003</year><fpage>2896</fpage><lpage>2902</lpage><pub-id pub-id-type="pmid">12417588</pub-id></element-citation></ref><ref id="b0605"><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name><surname>Lesort</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>G.</given-names></name></person-group><article-title>Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons</article-title><source>Neuroscience</source><volume>99</volume><issue>2</issue><year>2000</year><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">10938436</pub-id></element-citation></ref><ref id="b0610"><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name><surname>Lesort</surname><given-names>M.</given-names></name><name><surname>Jope</surname><given-names>R.S.</given-names></name><name><surname>Johnson</surname><given-names>G.V.</given-names></name></person-group><article-title>Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3&#x003b2; and Fyn tyrosine kinase</article-title><source>J. Neurochem.</source><volume>72</volume><issue>2</issue><year>1999</year><fpage>576</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">9930729</pub-id></element-citation></ref><ref id="b0615"><element-citation publication-type="journal" id="h0615"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Shepardson</surname><given-names>N.E.</given-names></name><name><surname>Walsh</surname><given-names>D.M.</given-names></name><name><surname>Shankar</surname><given-names>G.M.</given-names></name><name><surname>Selkoe</surname><given-names>D.</given-names></name></person-group><article-title>Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake</article-title><source>Neuron</source><volume>62</volume><issue>6</issue><year>2009</year><fpage>788</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">19555648</pub-id></element-citation></ref><ref id="b0620"><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>E.</given-names></name></person-group><article-title>An update on type 2 diabetes mellitus as a risk factor for dementia</article-title><source>J. Alzheimers Dis.</source><volume>53</volume><issue>2</issue><year>2016</year><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">27163819</pub-id></element-citation></ref><ref id="b0625"><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.-H.</given-names></name><name><surname>Xie</surname><given-names>J.-Z.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Lv</surname><given-names>B.-L.</given-names></name><name><surname>Cheng</surname><given-names>X.-S.</given-names></name><name><surname>Du</surname><given-names>L.-L.</given-names></name></person-group><article-title>Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation</article-title><source>NeuroMol. Med.</source><volume>14</volume><issue>4</issue><year>2012</year><fpage>338</fpage><lpage>348</lpage></element-citation></ref><ref id="b0630"><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>W.</given-names></name></person-group><article-title>Enhancement of beta-amyloid oligomer accumulation after intracerebroventricular injection of streptozotocin, which involves central insulin signaling in a transgenic mouse model</article-title><source>NeuroReport</source><volume>25</volume><issue>16</issue><year>2014</year><fpage>1289</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">25202927</pub-id></element-citation></ref><ref id="b0635"><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.-d.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name></person-group><article-title>Impaired amyloid &#x003b2;-degrading enzymes in brain of streptozotocin-induced diabetic rats</article-title><source>J. Endocrinol. Invest.</source><volume>34</volume><issue>1</issue><year>2011</year><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20414044</pub-id></element-citation></ref><ref id="b0640"><element-citation publication-type="journal" id="h0640"><person-group person-group-type="author"><name><surname>Locke</surname><given-names>M.</given-names></name><name><surname>Anderson</surname><given-names>J.</given-names></name></person-group><article-title>NF-&#x003ba;B activation in organs from STZ-treated rats</article-title><source>Appl. Physiol. Nutr. Metab.</source><volume>36</volume><issue>1</issue><year>2011</year><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">21326386</pub-id></element-citation></ref><ref id="b0645"><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>K.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Fukushima</surname><given-names>A.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Boivin</surname><given-names>B.</given-names></name><name><surname>Galic</surname><given-names>S.</given-names></name></person-group><article-title>Reactive oxygen species enhance insulin sensitivity</article-title><source>Cell Metab.</source><volume>10</volume><issue>4</issue><year>2009</year><fpage>260</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">19808019</pub-id></element-citation></ref><ref id="b0650"><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name><surname>Lotfy</surname><given-names>M.</given-names></name><name><surname>Adeghate</surname><given-names>J.</given-names></name><name><surname>Kalasz</surname><given-names>H.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name><name><surname>Adeghate</surname><given-names>E.</given-names></name></person-group><article-title>Chronic complications of diabetes mellitus: a mini review</article-title><source>Curr. Diabetes Rev.</source><volume>13</volume><issue>1</issue><year>2017</year><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26472574</pub-id></element-citation></ref><ref id="b0655"><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name><surname>Lumeng</surname><given-names>C.N.</given-names></name><name><surname>Bodzin</surname><given-names>J.L.</given-names></name><name><surname>Saltiel</surname><given-names>A.R.</given-names></name></person-group><article-title>Obesity induces a phenotypic switch in adipose tissue macrophage polarization</article-title><source>J. Clin. Investig.</source><volume>117</volume><issue>1</issue><year>2007</year><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">17200717</pub-id></element-citation></ref><ref id="b0660"><element-citation publication-type="journal" id="h0660"><person-group person-group-type="author"><name><surname>L&#x000fc;th</surname><given-names>H.-J.</given-names></name><name><surname>Ogunlade</surname><given-names>V.</given-names></name><name><surname>Kuhla</surname><given-names>B.</given-names></name><name><surname>Kientsch-Engel</surname><given-names>R.</given-names></name><name><surname>Stahl</surname><given-names>P.</given-names></name><name><surname>Webster</surname><given-names>J.</given-names></name></person-group><article-title>Age-and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains</article-title><source>Cereb. Cortex</source><volume>15</volume><issue>2</issue><year>2004</year><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">15238435</pub-id></element-citation></ref><ref id="b0665"><element-citation publication-type="journal" id="h0665"><person-group person-group-type="author"><name><surname>Maassen</surname><given-names>J.A.</given-names></name><name><surname>&#x02019;T Hart</surname><given-names>L.M.</given-names></name><name><surname>Van Essen</surname><given-names>E.</given-names></name><name><surname>Heine</surname><given-names>R.J.</given-names></name><name><surname>Nijpels</surname><given-names>G.</given-names></name><name><surname>Jahangir Tafrechi</surname><given-names>R.S.</given-names></name></person-group><article-title>Mitochondrial diabetes: molecular mechanisms and clinical presentation</article-title><source>Diabetes.</source><volume>53</volume><issue>Suppl 1</issue><year>2004</year><fpage>S103</fpage><lpage>S109</lpage><pub-id pub-id-type="pmid">14749274</pub-id></element-citation></ref><ref id="b0670"><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name><surname>Majeed</surname><given-names>A.</given-names></name><name><surname>El-Sayed</surname><given-names>A.A.</given-names></name><name><surname>Khoja</surname><given-names>T.</given-names></name><name><surname>Alshamsan</surname><given-names>R.</given-names></name><name><surname>Millett</surname><given-names>C.</given-names></name><name><surname>Rawaf</surname><given-names>S.</given-names></name></person-group><article-title>Diabetes in the Middle-East and North Africa: an update</article-title><source>Diabetes Res. Clin. Pract.</source><volume>103</volume><issue>2</issue><year>2014</year><fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">24300017</pub-id></element-citation></ref><ref id="b0675"><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name><surname>Mandelkow</surname><given-names>E.M.</given-names></name><name><surname>Biernat</surname><given-names>J.</given-names></name><name><surname>Drewes</surname><given-names>G.</given-names></name><name><surname>Gustke</surname><given-names>N.</given-names></name><name><surname>Trinczek</surname><given-names>B.</given-names></name><name><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group><article-title>Tau domains, phosphorylation, and interactions with microtubules</article-title><source>Neurobiol. Aging</source><volume>16</volume><issue>3</issue><year>1995</year><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">7566345</pub-id></element-citation></ref><ref id="b0680"><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name><surname>Marciniak</surname><given-names>E.</given-names></name><name><surname>Leboucher</surname><given-names>A.</given-names></name><name><surname>Caron</surname><given-names>E.</given-names></name><name><surname>Ahmed</surname><given-names>T.</given-names></name><name><surname>Tailleux</surname><given-names>A.</given-names></name><name><surname>Dumont</surname><given-names>J.</given-names></name></person-group><article-title>Tau deletion promotes brain insulin resistance</article-title><source>J. Exp. Med.</source><volume>214</volume><issue>8</issue><year>2017</year><fpage>2257</fpage><lpage>2269</lpage><pub-id pub-id-type="pmid">28652303</pub-id></element-citation></ref><ref id="b0685"><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name><surname>Mattson</surname><given-names>M.P.</given-names></name><name><surname>Gleichmann</surname><given-names>M.</given-names></name><name><surname>Cheng</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondria in neuroplasticity and neurological disorders</article-title><source>Neuron</source><volume>60</volume><issue>5</issue><year>2008</year><fpage>748</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">19081372</pub-id></element-citation></ref><ref id="b0690"><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name><surname>Mauch</surname><given-names>D.H.</given-names></name><name><surname>N&#x000e4;gler</surname><given-names>K.</given-names></name><name><surname>Schumacher</surname><given-names>S.</given-names></name><name><surname>G&#x000f6;ritz</surname><given-names>C.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>E.-C.</given-names></name><name><surname>Otto</surname><given-names>A.</given-names></name></person-group><article-title>CNS synaptogenesis promoted by glia-derived cholesterol</article-title><source>Science (New York, NY)</source><volume>294</volume><issue>5545</issue><year>2001</year><fpage>1354</fpage><lpage>1357</lpage></element-citation></ref><ref id="b0695"><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>E.G.</given-names></name><name><surname>McGeer</surname><given-names>P.L.</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy</article-title><source>J. Alzheimers Dis.</source><volume>19</volume><issue>1</issue><year>2010</year><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">20061650</pub-id></element-citation></ref><ref id="b0700"><element-citation publication-type="journal" id="h0700"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G.M.</given-names></name><name><surname>Knopman</surname><given-names>D.S.</given-names></name><name><surname>Chertkow</surname><given-names>H.</given-names></name><name><surname>Hyman</surname><given-names>B.T.</given-names></name><name><surname>Jack</surname><given-names>C.R.</given-names><suffix>Jr.</suffix></name><name><surname>Kawas</surname><given-names>C.H.</given-names></name></person-group><article-title>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimer's Dementia: J. Alzheimer's Assoc.</source><volume>7</volume><issue>3</issue><year>2011</year><fpage>263</fpage><lpage>269</lpage></element-citation></ref><ref id="b0705"><element-citation publication-type="journal" id="h0705"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>M.</given-names></name></person-group><article-title>An overview on the clinical development of tau-based therapeutics</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><issue>4</issue><year>2018</year></element-citation></ref><ref id="b0710"><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name><surname>Mehlhorn</surname><given-names>G.</given-names></name><name><surname>Hollborn</surname><given-names>M.</given-names></name><name><surname>Schliebs</surname><given-names>R.</given-names></name></person-group><article-title>Induction of cytokines in glial cells surrounding cortical &#x003b2;-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology</article-title><source>Int. J. Dev. Neurosci.</source><volume>18</volume><issue>4&#x02013;5</issue><year>2000</year><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">10817926</pub-id></element-citation></ref><ref id="b0715"><element-citation publication-type="journal" id="h0715"><person-group person-group-type="author"><name><surname>Mendoza-Herrera</surname><given-names>K.</given-names></name><name><surname>Aradillas-Garc&#x000ed;a</surname><given-names>C.</given-names></name><name><surname>Mej&#x000ed;a-Diaz</surname><given-names>M.</given-names></name><name><surname>Alegr&#x000ed;a-Torres</surname><given-names>J.</given-names></name><name><surname>Garay-Sevilla</surname><given-names>M.</given-names></name><name><surname>Luevano-Contreras</surname><given-names>C.</given-names></name></person-group><article-title>Association of dietary advanced glycation end products with metabolic syndrome in young mexican adults</article-title><source>Medicines</source><volume>5</volume><issue>4</issue><year>2018</year><fpage>128</fpage></element-citation></ref><ref id="b0720"><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Y.</given-names></name><name><surname>Baldwin</surname><given-names>C.T.</given-names></name><name><surname>Bowirrat</surname><given-names>A.</given-names></name><name><surname>Waraska</surname><given-names>K.</given-names></name><name><surname>Inzelberg</surname><given-names>R.</given-names></name><name><surname>Friedland</surname><given-names>R.P.</given-names></name></person-group><article-title>Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community</article-title><source>Am. J. Hum. Genet.</source><volume>78</volume><issue>5</issue><year>2006</year><fpage>871</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">16642441</pub-id></element-citation></ref><ref id="b0725"><element-citation publication-type="journal" id="h0725"><person-group person-group-type="author"><name><surname>Miklossy</surname><given-names>J.</given-names></name><name><surname>Qing</surname><given-names>H.</given-names></name><name><surname>Radenovic</surname><given-names>A.</given-names></name><name><surname>Kis</surname><given-names>A.</given-names></name><name><surname>Vileno</surname><given-names>B.</given-names></name><name><surname>L&#x000e0;szl&#x000f3;</surname><given-names>F.</given-names></name></person-group><article-title>Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes</article-title><source>Neurobiol. Aging</source><volume>31</volume><issue>9</issue><year>2010</year><fpage>1503</fpage><lpage>1515</lpage><pub-id pub-id-type="pmid">18950899</pub-id></element-citation></ref><ref id="b0730"><element-citation publication-type="journal" id="h0730"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>B.W.</given-names></name><name><surname>Willett</surname><given-names>K.C.</given-names></name><name><surname>Desilets</surname><given-names>A.R.</given-names></name></person-group><article-title>Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease</article-title><source>Ann. Pharmacother.</source><volume>45</volume><issue>11</issue><year>2011</year><fpage>1416</fpage><lpage>1424</lpage><pub-id pub-id-type="pmid">22028424</pub-id></element-citation></ref><ref id="b0735"><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name><surname>Moloney</surname><given-names>A.M.</given-names></name><name><surname>Griffin</surname><given-names>R.J.</given-names></name><name><surname>Timmons</surname><given-names>S.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>R.</given-names></name><name><surname>Ravid</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>C.</given-names></name></person-group><article-title>Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling</article-title><source>Neurobiol. Aging</source><volume>31</volume><issue>2</issue><year>2010</year><fpage>224</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">18479783</pub-id></element-citation></ref><ref id="b0740"><element-citation publication-type="journal" id="h0740"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>P.I.</given-names></name><name><surname>Santos</surname><given-names>M.S.</given-names></name><name><surname>Seica</surname><given-names>R.</given-names></name><name><surname>Oliveira</surname><given-names>C.R.</given-names></name></person-group><article-title>Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes</article-title><source>J. Neurol. Sci.</source><volume>257</volume><issue>1&#x02013;2</issue><year>2007</year><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">17316694</pub-id></element-citation></ref><ref id="b0745"><element-citation publication-type="journal" id="h0745"><person-group person-group-type="author"><name><surname>Newcombe</surname><given-names>E.A.</given-names></name><name><surname>Camats-Perna</surname><given-names>J.</given-names></name><name><surname>Silva</surname><given-names>M.L.</given-names></name><name><surname>Valmas</surname><given-names>N.</given-names></name><name><surname>Huat</surname><given-names>T.J.</given-names></name><name><surname>Medeiros</surname><given-names>R.</given-names></name></person-group><article-title>Inflammation: the link between comorbidities, genetics, and Alzheimer's disease</article-title><source>J. Neuroinflam.</source><volume>15</volume><issue>1</issue><year>2018</year><fpage>276</fpage></element-citation></ref><ref id="b0750"><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name><surname>Okabayashi</surname><given-names>S.</given-names></name><name><surname>Shimozawa</surname><given-names>N.</given-names></name><name><surname>Yasutomi</surname><given-names>Y.</given-names></name><name><surname>Yanagisawa</surname><given-names>K.</given-names></name><name><surname>Kimura</surname><given-names>N.</given-names></name></person-group><article-title>Diabetes mellitus accelerates A&#x003b2; pathology in brain accompanied by enhanced GA&#x003b2; generation in nonhuman primates</article-title><source>PLoS ONE</source><volume>10</volume><issue>2</issue><year>2015</year><object-id pub-id-type="publisher-id">e0117362</object-id></element-citation></ref><ref id="b0755"><element-citation publication-type="journal" id="h0755"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N.</given-names></name><name><surname>Parker</surname><given-names>J.L.</given-names></name><name><surname>Lugus</surname><given-names>J.J.</given-names></name><name><surname>Walsh</surname><given-names>K.</given-names></name></person-group><article-title>Adipokines in inflammation and metabolic disease</article-title><source>Nat. Rev. Immunol.</source><volume>11</volume><issue>2</issue><year>2011</year><fpage>85</fpage><pub-id pub-id-type="pmid">21252989</pub-id></element-citation></ref><ref id="b0760"><element-citation publication-type="journal" id="h0760"><person-group person-group-type="author"><name><surname>Ouwens</surname><given-names>D.M.</given-names></name><name><surname>van Duinkerken</surname><given-names>E.</given-names></name><name><surname>Schoonenboom</surname><given-names>S.N.M.</given-names></name><name><surname>de Wiza</surname><given-names>D.H.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>van Golen</surname><given-names>L.</given-names></name></person-group><article-title>Cerebrospinal fluid levels of Alzheimer&#x02019;s disease biomarkers in middle-aged patients with type 1 diabetes</article-title><source>Diabetologia</source><volume>57</volume><issue>10</issue><year>2014</year><fpage>2208</fpage><lpage>2214</lpage><pub-id pub-id-type="pmid">25034377</pub-id></element-citation></ref><ref id="b0765"><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name><surname>Palmert</surname><given-names>M.R.</given-names></name><name><surname>Usiak</surname><given-names>M.</given-names></name><name><surname>Mayeux</surname><given-names>R.</given-names></name><name><surname>Raskind</surname><given-names>M.</given-names></name><name><surname>Tourtellotte</surname><given-names>W.W.</given-names></name><name><surname>Younkin</surname><given-names>S.G.</given-names></name></person-group><article-title>Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease</article-title><source>Neurology.</source><volume>40</volume><issue>7</issue><year>1990</year><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">2113204</pub-id></element-citation></ref><ref id="b0770"><element-citation publication-type="journal" id="h0770"><person-group person-group-type="author"><name><surname>Papon</surname><given-names>M.-A.</given-names></name><name><surname>El Khoury</surname><given-names>N.B.</given-names></name><name><surname>Marcouiller</surname><given-names>F.</given-names></name><name><surname>Julien</surname><given-names>C.</given-names></name><name><surname>Morin</surname><given-names>F.</given-names></name><name><surname>Bretteville</surname><given-names>A.</given-names></name></person-group><article-title>Deregulation of protein phosphatase 2A and hyperphosphorylation of &#x003c4; protein following onset of diabetes in NOD mice</article-title><source>Diabetes</source><volume>62</volume><issue>2</issue><year>2013</year><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">22961084</pub-id></element-citation></ref><ref id="b0775"><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Santani</surname><given-names>D.</given-names></name></person-group><article-title>Role of NF-kappa B in the pathogenesis of diabetes and its associated complications</article-title><source>Pharmacol. Rep.: PR</source><volume>61</volume><issue>4</issue><year>2009</year><fpage>595</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">19815941</pub-id></element-citation></ref><ref id="b0780"><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name><surname>Peila</surname><given-names>R.</given-names></name><name><surname>Rodriguez</surname><given-names>B.L.</given-names></name><name><surname>Launer</surname><given-names>L.J.</given-names></name></person-group><article-title>Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study</article-title><source>Diabetes</source><volume>51</volume><issue>4</issue><year>2002</year><fpage>1256</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">11916953</pub-id></element-citation></ref><ref id="b0785"><element-citation publication-type="journal" id="h0785"><person-group person-group-type="author"><name><surname>Phung</surname><given-names>K.T.T.</given-names></name><name><surname>Chaaya</surname><given-names>M.</given-names></name><name><surname>Prince</surname><given-names>M.</given-names></name><name><surname>Atweh</surname><given-names>S.</given-names></name><name><surname>El Asmar</surname><given-names>K.</given-names></name><name><surname>Karam</surname><given-names>G.</given-names></name></person-group><article-title>Dementia prevalence, care arrangement, and access to care in Lebanon: A pilot study</article-title><source>Alzheimer's Dementia: J. Alzheimer's Assoc.</source><volume>13</volume><issue>12</issue><year>2017</year><fpage>1317</fpage><lpage>1326</lpage></element-citation></ref><ref id="b0790"><element-citation publication-type="journal" id="h0790"><person-group person-group-type="author"><name><surname>Picone</surname><given-names>P.</given-names></name><name><surname>Giacomazza</surname><given-names>D.</given-names></name><name><surname>Vetri</surname><given-names>V.</given-names></name><name><surname>Carrotta</surname><given-names>R.</given-names></name><name><surname>Militello</surname><given-names>V.</given-names></name><name><surname>San Biagio</surname><given-names>P.L.</given-names></name></person-group><article-title>Insulin-activated Akt rescues Abeta oxidative stress-induced cell death by orchestrating molecular trafficking</article-title><source>Aging Cell</source><volume>10</volume><issue>5</issue><year>2011</year><fpage>832</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">21624038</pub-id></element-citation></ref><ref id="b0795"><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name><surname>Pintana</surname><given-names>H.</given-names></name><name><surname>Apaijai</surname><given-names>N.</given-names></name><name><surname>Pratchayasakul</surname><given-names>W.</given-names></name><name><surname>Chattipakorn</surname><given-names>N.</given-names></name><name><surname>Chattipakorn</surname><given-names>S.C.</given-names></name></person-group><article-title>Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats</article-title><source>Life Sci.</source><volume>91</volume><issue>11&#x02013;12</issue><year>2012</year><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">22925597</pub-id></element-citation></ref><ref id="b0800"><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name><surname>Pintana</surname><given-names>H.</given-names></name><name><surname>Apaijai</surname><given-names>N.</given-names></name><name><surname>Chattipakorn</surname><given-names>N.</given-names></name><name><surname>Chattipakorn</surname><given-names>S.C.</given-names></name></person-group><article-title>DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats</article-title><source>J. Endocrinol.</source><volume>218</volume><issue>1</issue><year>2013</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">23591914</pub-id></element-citation></ref><ref id="b0805"><element-citation publication-type="journal" id="h0805"><person-group person-group-type="author"><name><surname>Planel</surname><given-names>E.</given-names></name><name><surname>Richter</surname><given-names>K.E.</given-names></name><name><surname>Nolan</surname><given-names>C.E.</given-names></name><name><surname>Finley</surname><given-names>J.E.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name></person-group><article-title>Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia</article-title><source>J. Neurosci.: Off. J. Soc. Neurosci.</source><volume>27</volume><issue>12</issue><year>2007</year><fpage>3090</fpage><lpage>3097</lpage></element-citation></ref><ref id="b0810"><element-citation publication-type="journal" id="h0810"><person-group person-group-type="author"><name><surname>Price</surname><given-names>J.C.</given-names></name><name><surname>Klunk</surname><given-names>W.E.</given-names></name><name><surname>Lopresti</surname><given-names>B.J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Hoge</surname><given-names>J.A.</given-names></name><name><surname>Ziolko</surname><given-names>S.K.</given-names></name></person-group><article-title>Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B</article-title><source>J. Cereb. Blood Flow Metabolism: Off. J. Int. Soc. Cerebral Blood Flow Metabol.</source><volume>25</volume><issue>11</issue><year>2005</year><fpage>1528</fpage><lpage>1547</lpage></element-citation></ref><ref id="b0815"><element-citation publication-type="journal" id="h0815"><person-group person-group-type="author"><name><surname>Priyadarshini</surname><given-names>M.</given-names></name><name><surname>Kamal</surname><given-names>M.A.</given-names></name><name><surname>Greig</surname><given-names>N.H.</given-names></name><name><surname>Reale</surname><given-names>M.</given-names></name><name><surname>Abuzenadah</surname><given-names>A.M.</given-names></name><name><surname>Chaudhary</surname><given-names>A.G.</given-names></name></person-group><article-title>Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase</article-title><source>CNS Neurol. Disord.: Drug Targets</source><volume>11</volume><issue>4</issue><year>2012</year><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">22583431</pub-id></element-citation></ref><ref id="b0820"><element-citation publication-type="journal" id="h0820"><person-group person-group-type="author"><name><surname>Purkayastha</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Ahmed</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>D.</given-names></name></person-group><article-title>Neural dysregulation of peripheral insulin action and blood pressure by brain endoplasmic reticulum stress</article-title><source>Proc. Natl. Acad. Sci.</source><volume>108</volume><issue>7</issue><year>2011</year><fpage>2939</fpage><lpage>2944</lpage><pub-id pub-id-type="pmid">21282643</pub-id></element-citation></ref><ref id="b0825"><element-citation publication-type="journal" id="h0825"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>H.</given-names></name><name><surname>John</surname><given-names>A.</given-names></name><name><surname>Howarth</surname><given-names>F.C.</given-names></name></person-group><article-title>Increased oxidative stress and mitochondrial dysfunction in zucker diabetic rat liver and brain</article-title><source>Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol., Biochem., Pharmacol.</source><volume>35</volume><issue>3</issue><year>2015</year><fpage>1241</fpage><lpage>1251</lpage></element-citation></ref><ref id="b0830"><element-citation publication-type="journal" id="h0830"><person-group person-group-type="author"><name><surname>Reitz</surname><given-names>C.</given-names></name><name><surname>Mayeux</surname><given-names>R.</given-names></name></person-group><article-title>Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers</article-title><source>Biochem. Pharmacol.</source><volume>88</volume><issue>4</issue><year>2014</year><fpage>640</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">24398425</pub-id></element-citation></ref><ref id="b0835"><element-citation publication-type="journal" id="h0835"><person-group person-group-type="author"><name><surname>Rohn</surname><given-names>T.T.</given-names></name><name><surname>Catlin</surname><given-names>L.W.</given-names></name><name><surname>Coonse</surname><given-names>K.G.</given-names></name><name><surname>Habig</surname><given-names>J.W.</given-names></name></person-group><article-title>Identification of an amino-terminal fragment of apolipoprotein E4 that localizes to neurofibrillary tangles of the Alzheimer's disease brain</article-title><source>Brain Res.</source><volume>1475</volume><year>2012</year><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">22902767</pub-id></element-citation></ref><ref id="b0840"><element-citation publication-type="journal" id="h0840"><person-group person-group-type="author"><name><surname>R&#x000f6;nnemaa</surname><given-names>E.</given-names></name><name><surname>Zethelius</surname><given-names>B.</given-names></name><name><surname>Sundel&#x000f6;f</surname><given-names>J.</given-names></name><name><surname>Sundstr&#x000f6;m</surname><given-names>J.</given-names></name><name><surname>Degerman-Gunnarsson</surname><given-names>M.</given-names></name><name><surname>Berne</surname><given-names>C.</given-names></name></person-group><article-title>Impaired insulin secretion increases the risk of Alzheimer disease</article-title><source>Neurology</source><volume>71</volume><issue>14</issue><year>2008</year><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">18401020</pub-id></element-citation></ref><ref id="b0845"><element-citation publication-type="journal" id="h0845"><person-group person-group-type="author"><name><surname>Rosenmann</surname><given-names>H.</given-names></name></person-group><article-title>CSF biomarkers for amyloid and tau pathology in Alzheimer's disease</article-title><source>J. Mol. Neurosci.: MN</source><volume>47</volume><issue>1</issue><year>2012</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">22058061</pub-id></element-citation></ref><ref id="b0850"><element-citation publication-type="journal" id="h0850"><person-group person-group-type="author"><name><surname>Saadi</surname><given-names>H.</given-names></name><name><surname>Nagelkerke</surname><given-names>N.</given-names></name><name><surname>Carruthers</surname><given-names>S.G.</given-names></name><name><surname>Benedict</surname><given-names>S.</given-names></name><name><surname>Abdulkhalek</surname><given-names>S.</given-names></name><name><surname>Reed</surname><given-names>R.</given-names></name></person-group><article-title>Association of TCF7L2 polymorphism with diabetes mellitus, metabolic syndrome, and markers of beta cell function and insulin resistance in a population-based sample of Emirati subjects</article-title><source>Diabetes Res. Clin. Pract.</source><volume>80</volume><issue>3</issue><year>2008</year><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">18282631</pub-id></element-citation></ref><ref id="b0855"><element-citation publication-type="journal" id="h0855"><person-group person-group-type="author"><name><surname>Saber-Ayad</surname><given-names>M.</given-names></name><name><surname>Manzoor</surname><given-names>S.</given-names></name><name><surname>El Serafi</surname><given-names>A.</given-names></name><name><surname>Mahmoud</surname><given-names>I.</given-names></name><name><surname>Hammoudeh</surname><given-names>S.</given-names></name><name><surname>Rani</surname><given-names>A.</given-names></name></person-group><article-title>The FTO rs9939609 &#x0201c;A&#x0201d; allele is associated with impaired fasting glucose and insulin resistance in Emirati population</article-title><source>Gene</source><volume>681</volume><year>2019</year><fpage>93</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">30273662</pub-id></element-citation></ref><ref id="b0860"><element-citation publication-type="journal" id="h0860"><person-group person-group-type="author"><name><surname>Salkovic-Petrisic</surname><given-names>M.</given-names></name><name><surname>Tribl</surname><given-names>F.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><name><surname>Hoyer</surname><given-names>S.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name></person-group><article-title>Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway</article-title><source>J. Neurochem.</source><volume>96</volume><issue>4</issue><year>2006</year><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">16412093</pub-id></element-citation></ref><ref id="b0865"><element-citation publication-type="journal" id="h0865"><person-group person-group-type="author"><name><surname>Sanghera</surname><given-names>D.K.</given-names></name><name><surname>Ortega</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name><name><surname>Ralhan</surname><given-names>S.K.</given-names></name><name><surname>Wander</surname><given-names>G.S.</given-names></name></person-group><article-title>Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk</article-title><source>BMC Med. Genet.</source><volume>9</volume><issue>1</issue><year>2008</year><fpage>59</fpage><pub-id pub-id-type="pmid">18598350</pub-id></element-citation></ref><ref id="b0870"><element-citation publication-type="journal" id="h0870"><person-group person-group-type="author"><name><surname>Sayas</surname><given-names>C.L.</given-names></name><name><surname>Moreno-Flores</surname><given-names>M.T.</given-names></name><name><surname>Avila</surname><given-names>J.</given-names></name><name><surname>Wandosell</surname><given-names>F.</given-names></name></person-group><article-title>The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation</article-title><source>J. Biol. Chem.</source><volume>274</volume><issue>52</issue><year>1999</year><fpage>37046</fpage><lpage>37052</lpage><pub-id pub-id-type="pmid">10601262</pub-id></element-citation></ref><ref id="b0875"><element-citation publication-type="journal" id="h0875"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M.I.</given-names></name><name><surname>Duncan</surname><given-names>B.B.</given-names></name><name><surname>Sharrett</surname><given-names>A.R.</given-names></name><name><surname>Lindberg</surname><given-names>G.</given-names></name><name><surname>Savage</surname><given-names>P.J.</given-names></name><name><surname>Offenbacher</surname><given-names>S.</given-names></name></person-group><article-title>Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study</article-title><source>Lancet (London, England).</source><volume>353</volume><issue>9165</issue><year>1999</year><fpage>1649</fpage><lpage>1652</lpage></element-citation></ref><ref id="b0880"><element-citation publication-type="journal" id="h0880"><person-group person-group-type="author"><name><surname>Seripa</surname><given-names>D.</given-names></name><name><surname>Solfrizzi</surname><given-names>V.</given-names></name><name><surname>Imbimbo</surname><given-names>B.P.</given-names></name><name><surname>Daniele</surname><given-names>A.</given-names></name><name><surname>Santamato</surname><given-names>A.</given-names></name><name><surname>Lozupone</surname><given-names>M.</given-names></name></person-group><article-title>Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium</article-title><source>Expert Rev. Neurother.</source><volume>16</volume><issue>3</issue><year>2016</year><fpage>259</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">26822031</pub-id></element-citation></ref><ref id="b0885"><element-citation publication-type="journal" id="h0885"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Cho</surname><given-names>K.W.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name></person-group><article-title>NF-&#x003ba;B&#x02013;inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action</article-title><source>Nat. Med.</source><volume>18</volume><issue>6</issue><year>2012</year><fpage>943</fpage><pub-id pub-id-type="pmid">22581287</pub-id></element-citation></ref><ref id="b0890"><element-citation publication-type="journal" id="h0890"><person-group person-group-type="author"><name><surname>Shentu</surname><given-names>Y.P.</given-names></name><name><surname>Huo</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>X.L.</given-names></name><name><surname>Gilbert</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Liuyang</surname><given-names>Z.Y.</given-names></name></person-group><article-title>CIP2A causes tau/APP phosphorylation, synaptopathy, and memory deficits in Alzheimer's disease</article-title><source>Cell Rep.</source><volume>24</volume><issue>3</issue><year>2018</year><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">30021167</pub-id></element-citation></ref><ref id="b0895"><element-citation publication-type="journal" id="h0895"><person-group person-group-type="author"><name><surname>Shimaoka</surname><given-names>I.</given-names></name><name><surname>Kamide</surname><given-names>K.</given-names></name><name><surname>Ohishi</surname><given-names>M.</given-names></name><name><surname>Katsuya</surname><given-names>T.</given-names></name><name><surname>Akasaka</surname><given-names>H.</given-names></name><name><surname>Saitoh</surname><given-names>S.</given-names></name></person-group><article-title>Association of gene polymorphism of the fat-mass and obesity-associated gene with insulin resistance in Japanese</article-title><source>Hypertens. Res.</source><volume>33</volume><issue>3</issue><year>2010</year><fpage>214</fpage><pub-id pub-id-type="pmid">20075932</pub-id></element-citation></ref><ref id="b0900"><element-citation publication-type="journal" id="h0900"><person-group person-group-type="author"><name><surname>Sims-Robinson</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>B.</given-names></name><name><surname>Rosko</surname><given-names>A.</given-names></name><name><surname>Feldman</surname><given-names>E.L.</given-names></name></person-group><article-title>How does diabetes accelerate Alzheimer disease pathology?</article-title><source>Nat. Rev. Neurol.</source><volume>6</volume><issue>10</issue><year>2010</year><fpage>551</fpage><pub-id pub-id-type="pmid">20842183</pub-id></element-citation></ref><ref id="b0905"><element-citation publication-type="journal" id="h0905"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>A.</given-names></name><name><surname>Turunen</surname><given-names>H.</given-names></name><name><surname>Ngandu</surname><given-names>T.</given-names></name><name><surname>Peltonen</surname><given-names>M.</given-names></name><name><surname>Lev&#x000e4;lahti</surname><given-names>E.</given-names></name><name><surname>Helisalmi</surname><given-names>S.</given-names></name></person-group><article-title>Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial</article-title><source>JAMA Neurol.</source><volume>75</volume><issue>4</issue><year>2018</year><fpage>462</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">29356827</pub-id></element-citation></ref><ref id="b0910"><element-citation publication-type="journal" id="h0910"><person-group person-group-type="author"><name><surname>Srikanth</surname><given-names>V.</given-names></name><name><surname>Westcott</surname><given-names>B.</given-names></name><name><surname>Forbes</surname><given-names>J.</given-names></name><name><surname>Phan</surname><given-names>T.G.</given-names></name><name><surname>Beare</surname><given-names>R.</given-names></name><name><surname>Venn</surname><given-names>A.</given-names></name></person-group><article-title>Methylglyoxal, cognitive function and cerebral atrophy in older people</article-title><source>J. Gerontol. Ser. A: Biomed. Sci. Med. Sci.</source><volume>68</volume><issue>1</issue><year>2012</year><fpage>68</fpage><lpage>73</lpage></element-citation></ref><ref id="b0915"><element-citation publication-type="journal" id="h0915"><person-group person-group-type="author"><name><surname>Steen</surname><given-names>E.</given-names></name><name><surname>Terry</surname><given-names>B.M.</given-names></name><name><surname>Rivera</surname><given-names>J.E.</given-names></name><name><surname>Cannon</surname><given-names>J.L.</given-names></name><name><surname>Neely</surname><given-names>T.R.</given-names></name><name><surname>Tavares</surname><given-names>R.</given-names></name></person-group><article-title>Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease&#x02013;is this type 3 diabetes?</article-title><source>J. Alzheimer's Dis.</source><volume>7</volume><issue>1</issue><year>2005</year><fpage>63</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15750215</pub-id></element-citation></ref><ref id="b0920"><element-citation publication-type="journal" id="h0920"><person-group person-group-type="author"><name><surname>Stephen</surname><given-names>T.</given-names></name><name><surname>Cacciottolo</surname><given-names>M.</given-names></name><name><surname>Balu</surname><given-names>D.</given-names></name><name><surname>Morgan</surname><given-names>T.</given-names></name><name><surname>LaDu</surname><given-names>M.</given-names></name><name><surname>Finch</surname><given-names>C.</given-names></name></person-group><article-title>APOE genotype and sex affect microglial interactions with plaques in Alzheimer&#x02019;s disease mice</article-title><source>Acta Neuropath. Commun.</source><volume>7</volume><issue>1</issue><year>2019</year><fpage>82</fpage></element-citation></ref><ref id="b0925"><element-citation publication-type="journal" id="h0925"><person-group person-group-type="author"><name><surname>Strachan</surname><given-names>M.W.</given-names></name><name><surname>Deary</surname><given-names>I.J.</given-names></name><name><surname>Ewing</surname><given-names>F.M.</given-names></name><name><surname>Frier</surname><given-names>B.M.</given-names></name></person-group><article-title>Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes</article-title><source>Diabetes Care</source><volume>23</volume><issue>3</issue><year>2000</year><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">10868856</pub-id></element-citation></ref><ref id="b0930"><element-citation publication-type="journal" id="h0930"><person-group person-group-type="author"><name><surname>Sulaiman</surname><given-names>N.</given-names></name><name><surname>Mahmoud</surname><given-names>I.</given-names></name><name><surname>Hussein</surname><given-names>A.</given-names></name><name><surname>Elbadawi</surname><given-names>S.</given-names></name><name><surname>Abusnana</surname><given-names>S.</given-names></name><name><surname>Zimmet</surname><given-names>P.</given-names></name></person-group><article-title>Diabetes risk score in the United Arab Emirates: a screening tool for the early detection of type 2 diabetes mellitus</article-title><source>BMJ Open Diabetes Res. Care</source><volume>6</volume><issue>1</issue><year>2018</year><object-id pub-id-type="publisher-id">e000489</object-id></element-citation></ref><ref id="b0935"><element-citation publication-type="journal" id="h0935"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>R.H.</given-names></name><name><surname>Khan</surname><given-names>S.M.</given-names></name></person-group><article-title>A &#x0201c;mitochondrial cascade hypothesis&#x0201d; for sporadic Alzheimer's disease</article-title><source>Med. Hypotheses</source><volume>63</volume><issue>1</issue><year>2004</year><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15193340</pub-id></element-citation></ref><ref id="b0940"><element-citation publication-type="journal" id="h0940"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>N.</given-names></name><name><surname>Uchio-Yamada</surname><given-names>K.</given-names></name><name><surname>Sawada</surname><given-names>K.</given-names></name><name><surname>Kunieda</surname><given-names>T.</given-names></name><name><surname>Takeuchi</surname><given-names>D.</given-names></name></person-group><article-title>Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A&#x003b2; deposition in an Alzheimer mouse model with diabetes</article-title><source>Proc. Natl. Acad. Sci.</source><volume>107</volume><issue>15</issue><year>2010</year><fpage>7036</fpage><lpage>7041</lpage><pub-id pub-id-type="pmid">20231468</pub-id></element-citation></ref><ref id="b0945"><element-citation publication-type="journal" id="h0945"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Scott</surname><given-names>D.A.</given-names></name><name><surname>Das</surname><given-names>U.</given-names></name><name><surname>Edland</surname><given-names>S.D.</given-names></name><name><surname>Radomski</surname><given-names>K.</given-names></name><name><surname>Koo</surname><given-names>E.H.</given-names></name></person-group><article-title>Early and selective impairments in axonal transport kinetics of synaptic cargoes induced by soluble amyloid beta-protein oligomers</article-title><source>Traffic (Copenhagen, Denmark)</source><volume>13</volume><issue>5</issue><year>2012</year><fpage>681</fpage><lpage>693</lpage></element-citation></ref><ref id="b0950"><element-citation publication-type="journal" id="h0950"><person-group person-group-type="author"><name><surname>Unoki</surname><given-names>H.</given-names></name><name><surname>Bujo</surname><given-names>H.</given-names></name><name><surname>Yamagishi</surname><given-names>S.-I.</given-names></name><name><surname>Takeuchi</surname><given-names>M.</given-names></name><name><surname>Imaizumi</surname><given-names>T.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name></person-group><article-title>Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes</article-title><source>Diabetes Res. Clin. Pract.</source><volume>76</volume><issue>2</issue><year>2007</year><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">17097186</pub-id></element-citation></ref><ref id="b0955"><element-citation publication-type="journal" id="h0955"><person-group person-group-type="author"><name><surname>Uronen</surname><given-names>R.-L.E.</given-names></name><name><surname>Huttunen</surname><given-names>H.J.</given-names></name></person-group><article-title>Genetic risk factors of Alzheimer&#x02019;s disease and cell-to-cell transmission of Tau</article-title><source>J. Neurol. Neuromed.</source><year>2016</year></element-citation></ref><ref id="b0960"><element-citation publication-type="journal" id="h0960"><person-group person-group-type="author"><name><surname>Van de Ree</surname><given-names>M.</given-names></name><name><surname>Huisman</surname><given-names>M.</given-names></name><name><surname>Princen</surname><given-names>H.</given-names></name><name><surname>Meinders</surname><given-names>A.</given-names></name><name><surname>Kluft</surname><given-names>C.</given-names></name><name><surname>Group</surname><given-names>D.-S.</given-names></name></person-group><article-title>Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus</article-title><source>Atherosclerosis.</source><volume>166</volume><issue>1</issue><year>2003</year><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">12482559</pub-id></element-citation></ref><ref id="b0965"><element-citation publication-type="journal" id="h0965"><person-group person-group-type="author"><name><surname>van Horssen</surname><given-names>J.</given-names></name><name><surname>van Schaik</surname><given-names>P.</given-names></name><name><surname>Witte</surname><given-names>M.</given-names></name></person-group><article-title>Inflammation and mitochondrial dysfunction: a vicious circle in neurodegenerative disorders?</article-title><source>Neurosci. Lett.</source><year>2017</year></element-citation></ref><ref id="b0970"><element-citation publication-type="journal" id="h0970"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>R.T.</given-names></name><name><surname>Viegas</surname><given-names>I.</given-names></name><name><surname>Barosa</surname><given-names>C.</given-names></name><name><surname>Marques</surname><given-names>C.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Rizza</surname><given-names>R.A.</given-names></name></person-group><article-title>Diabetes-associated variation in TCF7L2 Is not associated with hepatic or extrahepatic insulin resistance</article-title><source>Diabetes</source><volume>65</volume><issue>4</issue><year>2016</year><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">26822092</pub-id></element-citation></ref><ref id="b0975"><element-citation publication-type="journal" id="h0975"><person-group person-group-type="author"><name><surname>Vozarova</surname><given-names>B.</given-names></name><name><surname>Weyer</surname><given-names>C.</given-names></name><name><surname>Lindsay</surname><given-names>R.S.</given-names></name><name><surname>Pratley</surname><given-names>R.E.</given-names></name><name><surname>Bogardus</surname><given-names>C.</given-names></name><name><surname>Tataranni</surname><given-names>P.A.</given-names></name></person-group><article-title>High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes</article-title><source>Diabetes</source><volume>51</volume><issue>2</issue><year>2002</year><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">11812755</pub-id></element-citation></ref><ref id="b0980"><element-citation publication-type="journal" id="h0980"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>D.M.</given-names></name><name><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>Deciphering the molecular basis of memory failure in Alzheimer's disease</article-title><source>Neuron</source><volume>44</volume><issue>1</issue><year>2004</year><fpage>181</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">15450169</pub-id></element-citation></ref><ref id="b0985"><element-citation publication-type="journal" id="h0985"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>D.M.</given-names></name><name><surname>Klyubin</surname><given-names>I.</given-names></name><name><surname>Fadeeva</surname><given-names>J.V.</given-names></name><name><surname>Cullen</surname><given-names>W.K.</given-names></name><name><surname>Anwyl</surname><given-names>R.</given-names></name><name><surname>Wolfe</surname><given-names>M.S.</given-names></name></person-group><article-title>Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo</article-title><source>Nature</source><volume>416</volume><issue>6880</issue><year>2002</year><fpage>535</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">11932745</pub-id></element-citation></ref><ref id="b0990"><element-citation publication-type="journal" id="h0990"><person-group person-group-type="author"><name><surname>Westwood</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Baird</surname><given-names>A.L.</given-names></name><name><surname>Anand</surname><given-names>S.</given-names></name><name><surname>Nevado-Holgado</surname><given-names>A.J.</given-names></name><name><surname>Newby</surname><given-names>D.</given-names></name></person-group><article-title>The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer&#x02019;s pathology</article-title><source>Alzheimer's Res. Therapy</source><volume>9</volume><issue>1</issue><year>2017</year><fpage>31</fpage></element-citation></ref><ref id="b0995"><element-citation publication-type="journal" id="h0995"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Barnes</surname><given-names>G.T.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Tan</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Chou</surname><given-names>C.J.</given-names></name></person-group><article-title>Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance</article-title><source>J Clin Invest.</source><volume>112</volume><issue>12</issue><year>2003</year><fpage>1821</fpage><lpage>1830</lpage><pub-id pub-id-type="pmid">14679177</pub-id></element-citation></ref><ref id="b1000"><element-citation publication-type="journal" id="h1000"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name></person-group><article-title>Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes</article-title><source>J. Invest. Med.: Off. Publ. Am. Feder. Clin. Res.</source><volume>63</volume><issue>2</issue><year>2015</year><fpage>267</fpage><lpage>272</lpage></element-citation></ref><ref id="b1005"><element-citation publication-type="journal" id="h1005"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>S-i</given-names></name><name><surname>Maeda</surname><given-names>S.</given-names></name><name><surname>Matsui</surname><given-names>T.</given-names></name><name><surname>Ueda</surname><given-names>S.</given-names></name><name><surname>Fukami</surname><given-names>K.</given-names></name><name><surname>Okuda</surname><given-names>S.</given-names></name></person-group><article-title>Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes</article-title><source>Biochim. Biophys. Acta (BBA)-Gen. Sub.</source><volume>1820</volume><issue>5</issue><year>2012</year><fpage>663</fpage><lpage>671</lpage></element-citation></ref><ref id="b1010"><element-citation publication-type="journal" id="h1010"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>T.</given-names></name><name><surname>Yue</surname><given-names>W.</given-names></name></person-group><article-title>Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level</article-title><source>Mol. Cell. Neurosci.</source><volume>70</volume><year>2016</year><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">26640240</pub-id></element-citation></ref><ref id="b1015"><element-citation publication-type="journal" id="h1015"><person-group person-group-type="author"><name><surname>Yiannopoulou</surname><given-names>K.G.</given-names></name><name><surname>Papageorgiou</surname><given-names>S.G.</given-names></name></person-group><article-title>Current and future treatments for Alzheimer's disease</article-title><source>Therap. Adv. Neurol. Disord.</source><volume>6</volume><issue>1</issue><year>2013</year><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23277790</pub-id></element-citation></ref><ref id="b1020"><element-citation publication-type="journal" id="h1020"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.</given-names></name><name><surname>Kuret</surname><given-names>J.</given-names></name></person-group><article-title>C-terminal truncation modulates both nucleation and extension phases of &#x003c4; fibrillization</article-title><source>FEBS Lett.</source><volume>580</volume><issue>1</issue><year>2006</year><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">16364303</pub-id></element-citation></ref><ref id="b1025"><element-citation publication-type="journal" id="h1025"><person-group person-group-type="author"><name><surname>Zadjali</surname><given-names>F.</given-names></name><name><surname>Al-Yahyaee</surname><given-names>S.</given-names></name><name><surname>Hassan</surname><given-names>M.</given-names></name><name><surname>Albarwani</surname><given-names>S.</given-names></name><name><surname>Bayoumi</surname><given-names>R.</given-names></name></person-group><article-title>Association of adiponectin promoter variants with traits and clusters of metabolic syndrome in Arabs: family-based study</article-title><source>Gene</source><volume>527</volume><issue>2</issue><year>2013</year><fpage>663</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">23845780</pub-id></element-citation></ref><ref id="b1030"><element-citation publication-type="journal" id="h1030"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shentu</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>K.</given-names></name><name><surname>Mahaman</surname><given-names>Y.A.R.</given-names></name></person-group><article-title>CK2 phosphorylating I(2)(PP2A)/SET mediates tau pathology and cognitive impairment</article-title><source>Front. Mol. Neurosci.</source><volume>11</volume><year>2018</year><fpage>146</fpage><pub-id pub-id-type="pmid">29760653</pub-id></element-citation></ref><ref id="b1035"><element-citation publication-type="journal" id="h1035"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W.-Q.</given-names></name><name><surname>Alkon</surname><given-names>D.L.</given-names></name></person-group><article-title>Role of insulin and insulin receptor in learning and memory</article-title><source>Mol. Cell. Endocrinol.</source><volume>177</volume><issue>1&#x02013;2</issue><year>2001</year><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">11377828</pub-id></element-citation></ref><ref id="b1040"><element-citation publication-type="journal" id="h1040"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W.-Q.</given-names></name><name><surname>De Felice</surname><given-names>F.G.</given-names></name><name><surname>Fernandez</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lambert</surname><given-names>M.P.</given-names></name><name><surname>Quon</surname><given-names>M.J.</given-names></name></person-group><article-title>Amyloid beta oligomers induce impairment of neuronal insulin receptors</article-title><source>FASEB J.</source><volume>22</volume><issue>1</issue><year>2008</year><fpage>246</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">17720802</pub-id></element-citation></ref><ref id="b1045"><element-citation publication-type="journal" id="h1045"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>Q.</given-names></name><name><surname>Lv</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Gang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>Biomarkers for cognitive decline in patients with diabetes mellitus: evidence from clinical studies</article-title><source>Oncotarget</source><volume>9</volume><issue>7</issue><year>2017</year><fpage>7710</fpage><lpage>7726</lpage><pub-id pub-id-type="pmid">29484146</pub-id></element-citation></ref><ref id="b1050"><element-citation publication-type="journal" id="h1050"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W.-Q.</given-names></name><name><surname>Lacor</surname><given-names>P.N.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lambert</surname><given-names>M.P.</given-names></name><name><surname>Quon</surname><given-names>M.J.</given-names></name><name><surname>Krafft</surname><given-names>G.A.</given-names></name></person-group><article-title>Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric abeta</article-title><source>J. Biol. Chem.</source><volume>jbc</volume><year>2009</year><comment>M109. 011015</comment></element-citation></ref><ref id="b1055"><element-citation publication-type="journal" id="h1055"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>C.-C.</given-names></name><name><surname>Qiao</surname><given-names>W.</given-names></name><name><surname>Bu</surname><given-names>G.</given-names></name></person-group><article-title>Apolipoprotein E, receptors, and modulation of Alzheimer&#x02019;s disease</article-title><source>Biol. Psychiatry</source><volume>83</volume><issue>4</issue><year>2018</year><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">28434655</pub-id></element-citation></ref><ref id="b1060"><element-citation publication-type="journal" id="h1060"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>N.</given-names></name><name><surname>Weisgraber</surname><given-names>K.H.</given-names></name></person-group><article-title>Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure</article-title><source>J. Biol. Chem.</source><volume>284</volume><issue>10</issue><year>2009</year><fpage>6027</fpage><lpage>6031</lpage><pub-id pub-id-type="pmid">18948255</pub-id></element-citation></ref><ref id="b1065"><element-citation publication-type="journal" id="h1065"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Scott</surname><given-names>S.</given-names></name><name><surname>Shelton</surname><given-names>S.</given-names></name><name><surname>Crutcher</surname><given-names>K.</given-names></name></person-group><article-title>Cathepsin D-mediated proteolysis of apolipoprotein E: possible role in Alzheimer&#x02019;s disease</article-title><source>Neuroscience</source><volume>143</volume><issue>3</issue><year>2006</year><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">16997486</pub-id></element-citation></ref><ref id="b1070"><element-citation publication-type="journal" id="h1070"><person-group person-group-type="author"><name><surname>Zilka</surname><given-names>N.</given-names></name><name><surname>Filipcik</surname><given-names>P.</given-names></name><name><surname>Koson</surname><given-names>P.</given-names></name><name><surname>Fialova</surname><given-names>L.</given-names></name><name><surname>Skrabana</surname><given-names>R.</given-names></name><name><surname>Zilkova</surname><given-names>M.</given-names></name></person-group><article-title>Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo</article-title><source>FEBS Lett.</source><volume>580</volume><issue>15</issue><year>2006</year><fpage>3582</fpage><lpage>3588</lpage><pub-id pub-id-type="pmid">16753151</pub-id></element-citation></ref><ref id="b1075"><element-citation publication-type="journal" id="h1075"><person-group person-group-type="author"><name><surname>Zilkens</surname><given-names>R.R.</given-names></name><name><surname>Davis</surname><given-names>W.A.</given-names></name><name><surname>Spilsbury</surname><given-names>K.</given-names></name><name><surname>Semmens</surname><given-names>J.B.</given-names></name><name><surname>Bruce</surname><given-names>D.G.</given-names></name></person-group><article-title>Earlier age of dementia onset and shorter survival times in dementia patients with diabetes</article-title><source>Am. J. Epidemiol.</source><volume>177</volume><issue>11</issue><year>2013</year><fpage>1246</fpage><lpage>1254</lpage><pub-id pub-id-type="pmid">23543134</pub-id></element-citation></ref></ref-list><ack id="ak005"><sec id="s0050"><title>Acknowledgements</title><p id="p0070">Not applicable.</p></sec><sec id="s0055"><title>Funding</title><p id="p0075">This work was funded by <funding-source id="gp005">United Arab Emirates University</funding-source> Start-up Grant (31M411).</p></sec><sec sec-type="data-availability" id="s0060"><title>Availability of data and materials</title><p id="p0080">Not applicable.</p></sec><sec id="s0065"><title>Author&#x02019;s contributions</title><p id="p0085">This manuscript was written by RJ. Modifications were suggested by RB. AS and RB critically edited the final manuscript. All authors read and approved the manuscript.</p></sec><sec id="s0070"><title>Ethics approval and consent to participate</title><p id="p0090">Not applicable.</p></sec><sec id="s0075"><title>Consent for publication</title><p id="p0095">Not applicable.</p></sec></ack><fn-group><fn id="d31e200"><p id="np005">Peer review under responsibility of King Saud University.</p></fn></fn-group></back></article>